JP2017525700A - ピラゾール類 - Google Patents
ピラゾール類 Download PDFInfo
- Publication number
- JP2017525700A JP2017525700A JP2017508553A JP2017508553A JP2017525700A JP 2017525700 A JP2017525700 A JP 2017525700A JP 2017508553 A JP2017508553 A JP 2017508553A JP 2017508553 A JP2017508553 A JP 2017508553A JP 2017525700 A JP2017525700 A JP 2017525700A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrazole
- pyrazol
- phenyl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003217 pyrazoles Chemical class 0.000 title abstract description 4
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 194
- 125000005843 halogen group Chemical group 0.000 claims description 157
- -1 substituent halogen Chemical class 0.000 claims description 76
- 125000000217 alkyl group Chemical group 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 61
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 58
- 125000003545 alkoxy group Chemical group 0.000 claims description 54
- 125000001424 substituent group Chemical group 0.000 claims description 52
- 229910052736 halogen Inorganic materials 0.000 claims description 45
- 150000002367 halogens Chemical class 0.000 claims description 41
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 37
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
- 208000035475 disorder Diseases 0.000 claims description 33
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 24
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims description 24
- 206010015037 epilepsy Diseases 0.000 claims description 23
- 239000012453 solvate Substances 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 150000001204 N-oxides Chemical class 0.000 claims description 17
- 206010010904 Convulsion Diseases 0.000 claims description 16
- 208000002193 Pain Diseases 0.000 claims description 14
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 9
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 150000002431 hydrogen Chemical group 0.000 claims description 7
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 208000016285 Movement disease Diseases 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 6
- 230000036407 pain Effects 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 208000012661 Dyskinesia Diseases 0.000 claims description 5
- 208000019022 Mood disease Diseases 0.000 claims description 5
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 230000000926 neurological effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 108010054200 NR2B NMDA receptor Proteins 0.000 claims description 4
- 208000029560 autism spectrum disease Diseases 0.000 claims description 4
- 230000003542 behavioural effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 208000024714 major depressive disease Diseases 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- ISRPGJCSMGGLSW-UHFFFAOYSA-N BrC1=CC=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C Chemical compound BrC1=CC=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C ISRPGJCSMGGLSW-UHFFFAOYSA-N 0.000 claims description 3
- YZCWRAFJWAFRHN-UHFFFAOYSA-N BrC1=CC=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C Chemical compound BrC1=CC=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C YZCWRAFJWAFRHN-UHFFFAOYSA-N 0.000 claims description 3
- XYCBFPMJNPHKTB-UHFFFAOYSA-N CN1N=C(C=C1CN1N=CC(=C1)C1=CC=C(C=C1)C(F)(F)F)C Chemical compound CN1N=C(C=C1CN1N=CC(=C1)C1=CC=C(C=C1)C(F)(F)F)C XYCBFPMJNPHKTB-UHFFFAOYSA-N 0.000 claims description 3
- FDYFJXNCCIBNPD-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C)C(F)(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C)C(F)(F)F FDYFJXNCCIBNPD-UHFFFAOYSA-N 0.000 claims description 3
- LVYDQZJCZSJMBO-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C)C(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C)C(F)F LVYDQZJCZSJMBO-UHFFFAOYSA-N 0.000 claims description 3
- CRTYJRKVIQBRIW-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CCC=1C(=NNC=1C)C)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CCC=1C(=NNC=1C)C)OC(F)F CRTYJRKVIQBRIW-UHFFFAOYSA-N 0.000 claims description 3
- FKNGDDYLLFMSCD-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1C=NN(C=1)CCC=1C(=NNC=1C)C Chemical compound ClC1=CC=C(C=C1)C=1C=NN(C=1)CCC=1C(=NNC=1C)C FKNGDDYLLFMSCD-UHFFFAOYSA-N 0.000 claims description 3
- XXULOVVPELJMEY-UHFFFAOYSA-N ClC=1C=C(C=C(C=1)C(F)F)C=1C=NN(C=1)CC1=NNC=C1 Chemical compound ClC=1C=C(C=C(C=1)C(F)F)C=1C=NN(C=1)CC1=NNC=C1 XXULOVVPELJMEY-UHFFFAOYSA-N 0.000 claims description 3
- FDBPKEPRZDXSQA-UHFFFAOYSA-N ClC=1C=C(C=C(C=1)OC(F)F)C=1C=NN(C=1)CC1=NNC=C1 Chemical compound ClC=1C=C(C=C(C=1)OC(F)F)C=1C=NN(C=1)CC1=NNC=C1 FDBPKEPRZDXSQA-UHFFFAOYSA-N 0.000 claims description 3
- TVHCUYDPYVKDHI-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NNC=C1CC)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NNC=C1CC)F TVHCUYDPYVKDHI-UHFFFAOYSA-N 0.000 claims description 3
- PAPFAZHJWWEGNJ-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1C(=NNC=1C)C)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1C(=NNC=1C)C)F PAPFAZHJWWEGNJ-UHFFFAOYSA-N 0.000 claims description 3
- MQKNJFNIYSGNHY-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1Cl)C=1C=NN(C=1)CC=1C(=NNC=1C)C)F Chemical compound FC(OC=1C=C(C=CC=1Cl)C=1C=NN(C=1)CC=1C(=NNC=1C)C)F MQKNJFNIYSGNHY-UHFFFAOYSA-N 0.000 claims description 3
- LHMLJRCNGQZNHL-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NNC=C1)F Chemical compound FC(OC=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NNC=C1)F LHMLJRCNGQZNHL-UHFFFAOYSA-N 0.000 claims description 3
- WTJLEJBVIDJMFC-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1C=NN(C=1)C)F Chemical compound FC(OC=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1C=NN(C=1)C)F WTJLEJBVIDJMFC-UHFFFAOYSA-N 0.000 claims description 3
- KYGBERMNMHOSMC-UHFFFAOYSA-N FC=1C=C(C=C(C=1)F)C=1C=NN(C=1)CC1=CC(=NN1C)C Chemical compound FC=1C=C(C=C(C=1)F)C=1C=NN(C=1)CC1=CC(=NN1C)C KYGBERMNMHOSMC-UHFFFAOYSA-N 0.000 claims description 3
- FBYLDXMRENBYNM-UHFFFAOYSA-N FC=1C=C(C=C(C=1)F)C=1C=NN(C=1)CC1=NN(C=C1)C Chemical compound FC=1C=C(C=C(C=1)F)C=1C=NN(C=1)CC1=NN(C=C1)C FBYLDXMRENBYNM-UHFFFAOYSA-N 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 201000009916 Postpartum depression Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
- 150000000659 7-membered carbocyclic compounds Chemical class 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- ANQAUDCJANAJOF-UHFFFAOYSA-N BrC=1C=C(C=CC=1)C=1C=NN(C=1)CC1=CC(=NN1C)C Chemical compound BrC=1C=C(C=CC=1)C=1C=NN(C=1)CC1=CC(=NN1C)C ANQAUDCJANAJOF-UHFFFAOYSA-N 0.000 claims description 2
- NHIDZRFOLGDIRM-UHFFFAOYSA-N CN1N=C(C=C1)CN1N=CC(=C1)C1=CC(=CC=C1)C(F)(F)F Chemical compound CN1N=C(C=C1)CN1N=CC(=C1)C1=CC(=CC=C1)C(F)(F)F NHIDZRFOLGDIRM-UHFFFAOYSA-N 0.000 claims description 2
- CPBUZCHPDATVEU-UHFFFAOYSA-N CN1N=C(C=C1)CN1N=CC(=C1)C1=CC(=CC=C1)OC(F)(F)F Chemical compound CN1N=C(C=C1)CN1N=CC(=C1)C1=CC(=CC=C1)OC(F)(F)F CPBUZCHPDATVEU-UHFFFAOYSA-N 0.000 claims description 2
- IOTYDSRQXWYEOM-UHFFFAOYSA-N CN1N=C(C=C1CN1N=CC(=C1)C1=CC(=CC=C1)OC(F)(F)F)C Chemical compound CN1N=C(C=C1CN1N=CC(=C1)C1=CC(=CC=C1)OC(F)(F)F)C IOTYDSRQXWYEOM-UHFFFAOYSA-N 0.000 claims description 2
- TXJIMPPHALVHGH-UHFFFAOYSA-N CN1N=C(C=C1CN1N=CC(=C1)C1=CC=CC=C1)C Chemical compound CN1N=C(C=C1CN1N=CC(=C1)C1=CC=CC=C1)C TXJIMPPHALVHGH-UHFFFAOYSA-N 0.000 claims description 2
- IVQOSXHMIKOTIP-UHFFFAOYSA-N CN1N=CC=C1CN1N=CC(=C1)C1=CC=CC=C1 Chemical compound CN1N=CC=C1CN1N=CC(=C1)C1=CC=CC=C1 IVQOSXHMIKOTIP-UHFFFAOYSA-N 0.000 claims description 2
- RNBFGQKOKMISQP-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1)C)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1)C)OC(F)F RNBFGQKOKMISQP-UHFFFAOYSA-N 0.000 claims description 2
- CJTATZNAJJRQJR-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C)C(F)(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C)C(F)(F)F CJTATZNAJJRQJR-UHFFFAOYSA-N 0.000 claims description 2
- RTURIZKUGANKMN-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C)C(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C)C(F)F RTURIZKUGANKMN-UHFFFAOYSA-N 0.000 claims description 2
- ZCZZFZFZUWEHRG-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C)OC(F)F ZCZZFZFZUWEHRG-UHFFFAOYSA-N 0.000 claims description 2
- PWOOSCZWCWFZKZ-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CN=CN1CC)C(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CN=CN1CC)C(F)F PWOOSCZWCWFZKZ-UHFFFAOYSA-N 0.000 claims description 2
- VCIYUUWUQVIFEO-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C(CC)CC)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C(CC)CC)OC(F)F VCIYUUWUQVIFEO-UHFFFAOYSA-N 0.000 claims description 2
- CRYKKCVVHRIZJU-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C)OC(F)F CRYKKCVVHRIZJU-UHFFFAOYSA-N 0.000 claims description 2
- LRTTWINCSMBJMM-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C1CCCC1)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C1CCCC1)OC(F)F LRTTWINCSMBJMM-UHFFFAOYSA-N 0.000 claims description 2
- PCHBMVPVCPSMLD-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)CC)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)CC)OC(F)F PCHBMVPVCPSMLD-UHFFFAOYSA-N 0.000 claims description 2
- PTYPZHOITALPCT-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NNC(=C1)CC)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NNC(=C1)CC)OC(F)F PTYPZHOITALPCT-UHFFFAOYSA-N 0.000 claims description 2
- BQEMIVBQABRGAT-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NNC(=C1)CCC)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NNC(=C1)CCC)OC(F)F BQEMIVBQABRGAT-UHFFFAOYSA-N 0.000 claims description 2
- GPZNPXAPAFLRLB-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NNC=C1)C(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NNC=C1)C(F)F GPZNPXAPAFLRLB-UHFFFAOYSA-N 0.000 claims description 2
- WXIFVEVHNGMUHP-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NNC=C1)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NNC=C1)OC(F)F WXIFVEVHNGMUHP-UHFFFAOYSA-N 0.000 claims description 2
- TYWLMLPPMXWFPX-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC=1C=NN(C=1)C)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC=1C=NN(C=1)C)OC(F)F TYWLMLPPMXWFPX-UHFFFAOYSA-N 0.000 claims description 2
- WQIJWPZIOIFLHO-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC=1C=NNC=1)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC=1C=NNC=1)OC(F)F WQIJWPZIOIFLHO-UHFFFAOYSA-N 0.000 claims description 2
- PLNFUYPBLOEXJI-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC=1C=NNC=1C)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC=1C=NNC=1C)OC(F)F PLNFUYPBLOEXJI-UHFFFAOYSA-N 0.000 claims description 2
- IZRNPSABLKZTLN-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC=1C=NNC=1CC)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC=1C=NNC=1CC)OC(F)F IZRNPSABLKZTLN-UHFFFAOYSA-N 0.000 claims description 2
- BHOUUDZNGWHFHC-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC=1N(N=CC=1)C)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC=1N(N=CC=1)C)OC(F)F BHOUUDZNGWHFHC-UHFFFAOYSA-N 0.000 claims description 2
- FMPLJMMZEDLVOK-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CCC=1C(=NNC=1C)C)C(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CCC=1C(=NNC=1C)C)C(F)F FMPLJMMZEDLVOK-UHFFFAOYSA-N 0.000 claims description 2
- WXLDTHJZQFCOMH-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CCC=1C=NN(C=1)CC)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CCC=1C=NN(C=1)CC)OC(F)F WXLDTHJZQFCOMH-UHFFFAOYSA-N 0.000 claims description 2
- OGSQOKYLXLIXRK-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CCC=1C=NNC=1)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CCC=1C=NNC=1)OC(F)F OGSQOKYLXLIXRK-UHFFFAOYSA-N 0.000 claims description 2
- IBXQVTJYUTXWOZ-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C Chemical compound ClC1=CC=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C IBXQVTJYUTXWOZ-UHFFFAOYSA-N 0.000 claims description 2
- LBYWWSCGWDYKNX-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1C=NN(C=1)CC1=CN=CN1CC Chemical compound ClC1=CC=C(C=C1)C=1C=NN(C=1)CC1=CN=CN1CC LBYWWSCGWDYKNX-UHFFFAOYSA-N 0.000 claims description 2
- WBSISSQHVCKNDV-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C Chemical compound ClC1=CC=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C WBSISSQHVCKNDV-UHFFFAOYSA-N 0.000 claims description 2
- ONBFZEJYXQDCRE-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1C=NN(C=1)CC1=NNC=C1 Chemical compound ClC1=CC=C(C=C1)C=1C=NN(C=1)CC1=NNC=C1 ONBFZEJYXQDCRE-UHFFFAOYSA-N 0.000 claims description 2
- HXXKCCOYYFKOHT-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1C=NN(C=1)CC=1C=NN(C=1)C Chemical compound ClC1=CC=C(C=C1)C=1C=NN(C=1)CC=1C=NN(C=1)C HXXKCCOYYFKOHT-UHFFFAOYSA-N 0.000 claims description 2
- OZKOQOLBOJMIRC-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1C=NN(C=1)CC=1N(N=CC=1)C Chemical compound ClC1=CC=C(C=C1)C=1C=NN(C=1)CC=1N(N=CC=1)C OZKOQOLBOJMIRC-UHFFFAOYSA-N 0.000 claims description 2
- WQTXJFYTZBONCP-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1C=NN(C=1)CC=1N=C2N(C=CC=C2)C=1 Chemical compound ClC1=CC=C(C=C1)C=1C=NN(C=1)CC=1N=C2N(C=CC=C2)C=1 WQTXJFYTZBONCP-UHFFFAOYSA-N 0.000 claims description 2
- GUJNOPVPJRXDCB-UHFFFAOYSA-N ClC=1C=C(C=CC=1Cl)C=1C=NN(C=1)C=1N(N=CC=1)C Chemical compound ClC=1C=C(C=CC=1Cl)C=1C=NN(C=1)C=1N(N=CC=1)C GUJNOPVPJRXDCB-UHFFFAOYSA-N 0.000 claims description 2
- HRKHYYJXFPDNFI-UHFFFAOYSA-N ClC=1C=C(C=CC=1F)C=1C=NN(C=1)C=1N(N=CC=1)C Chemical compound ClC=1C=C(C=CC=1F)C=1C=NN(C=1)C=1N(N=CC=1)C HRKHYYJXFPDNFI-UHFFFAOYSA-N 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- YUBYOLBZTMVIAV-UHFFFAOYSA-N FC(C)(F)C=1C=C(C=CC=1)C=1C=NN(C=1)CC1=NNC=C1 Chemical compound FC(C)(F)C=1C=C(C=CC=1)C=1C=NN(C=1)CC1=NNC=C1 YUBYOLBZTMVIAV-UHFFFAOYSA-N 0.000 claims description 2
- RQQJZPUPHSLLRR-UHFFFAOYSA-N FC(C)(F)C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NNC=C1 Chemical compound FC(C)(F)C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NNC=C1 RQQJZPUPHSLLRR-UHFFFAOYSA-N 0.000 claims description 2
- DDNUGAKPXYMUKR-UHFFFAOYSA-N FC(C)(F)C=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1C=NN(C=1)C Chemical compound FC(C)(F)C=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1C=NN(C=1)C DDNUGAKPXYMUKR-UHFFFAOYSA-N 0.000 claims description 2
- MVGNHQREGRFEQQ-UHFFFAOYSA-N FC(C)(F)C=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1C=NNC=1CC Chemical compound FC(C)(F)C=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1C=NNC=1CC MVGNHQREGRFEQQ-UHFFFAOYSA-N 0.000 claims description 2
- BGEGEEMDZPHRBZ-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C1=NN(C=C1)CC1=NNC(=C1)CN1N=CC(=C1)C1=CC(=C(C=C1)F)C(F)F)F Chemical compound FC(C=1C=C(C=CC=1F)C1=NN(C=C1)CC1=NNC(=C1)CN1N=CC(=C1)C1=CC(=C(C=C1)F)C(F)F)F BGEGEEMDZPHRBZ-UHFFFAOYSA-N 0.000 claims description 2
- SOTBKNXFRAXTAE-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=CC(=NN1C)C)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=CC(=NN1C)C)F SOTBKNXFRAXTAE-UHFFFAOYSA-N 0.000 claims description 2
- POUMWMHGHUZSLS-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NN(C=C1)C)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NN(C=C1)C)F POUMWMHGHUZSLS-UHFFFAOYSA-N 0.000 claims description 2
- GBHOKNOTTNNQTQ-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NN(C=C1)CC)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NN(C=C1)CC)F GBHOKNOTTNNQTQ-UHFFFAOYSA-N 0.000 claims description 2
- RQYYUIGRZDLILP-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NNC(=C1)CCC)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NNC(=C1)CCC)F RQYYUIGRZDLILP-UHFFFAOYSA-N 0.000 claims description 2
- SBFDBMKEWKLRSB-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NNC=C1)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NNC=C1)F SBFDBMKEWKLRSB-UHFFFAOYSA-N 0.000 claims description 2
- DOQIJLDPMKRTSR-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1C=NN(C=1)C)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1C=NN(C=1)C)F DOQIJLDPMKRTSR-UHFFFAOYSA-N 0.000 claims description 2
- DFRNAZVJXDTBSV-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1C=NNC=1C)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1C=NNC=1C)F DFRNAZVJXDTBSV-UHFFFAOYSA-N 0.000 claims description 2
- WJDFZNSBELJCKM-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1C=NNC=1CC)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1C=NNC=1CC)F WJDFZNSBELJCKM-UHFFFAOYSA-N 0.000 claims description 2
- QWQROZAMNURWBT-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1N(N=CC=1)C)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC=1N(N=CC=1)C)F QWQROZAMNURWBT-UHFFFAOYSA-N 0.000 claims description 2
- SKQPTLPPMSYEQN-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CCC=1C(=NNC=1C)C)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CCC=1C(=NNC=1C)C)F SKQPTLPPMSYEQN-UHFFFAOYSA-N 0.000 claims description 2
- JPDCMOOBLLIEFK-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CCC=1C=NNC=1)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CCC=1C=NNC=1)F JPDCMOOBLLIEFK-UHFFFAOYSA-N 0.000 claims description 2
- CIMZHFATSQYFET-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1)C=1C=NN(C=1)CC1=NNC=C1)F Chemical compound FC(OC=1C=C(C=CC=1)C=1C=NN(C=1)CC1=NNC=C1)F CIMZHFATSQYFET-UHFFFAOYSA-N 0.000 claims description 2
- IOOCAJSDFZHJMM-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NNC=C1CC)F Chemical compound FC(OC=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NNC=C1CC)F IOOCAJSDFZHJMM-UHFFFAOYSA-N 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 claims description 2
- 208000020358 Learning disease Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000037581 Persistent Infection Diseases 0.000 claims description 2
- 208000027520 Somatoform disease Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 201000003723 learning disability Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000000626 neurodegenerative effect Effects 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- TWITWMGSBLVJJS-UHFFFAOYSA-N BrC=1C=C(C=CC=1)C=1C=NN(C=1)CC1=NN(C=C1)C Chemical compound BrC=1C=C(C=CC=1)C=1C=NN(C=1)CC1=NN(C=C1)C TWITWMGSBLVJJS-UHFFFAOYSA-N 0.000 claims 1
- MYVGSZBCKCBYMQ-UHFFFAOYSA-N CN1N=C(C=C1)CN1N=CC(=C1)C1=NC=CC=C1 Chemical compound CN1N=C(C=C1)CN1N=CC(=C1)C1=NC=CC=C1 MYVGSZBCKCBYMQ-UHFFFAOYSA-N 0.000 claims 1
- MACPRACNPYALGP-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=CC(=NN1)C)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=CC(=NN1)C)F MACPRACNPYALGP-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract description 15
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 7
- 108091006082 receptor inhibitors Proteins 0.000 abstract description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 abstract 1
- 238000002844 melting Methods 0.000 description 52
- 230000008018 melting Effects 0.000 description 52
- 239000000203 mixture Substances 0.000 description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- UETNOXJRYZSQRA-UHFFFAOYSA-N 3-chloro-1,4-dimethylpyrazole Chemical compound CC1=CN(C)N=C1Cl UETNOXJRYZSQRA-UHFFFAOYSA-N 0.000 description 29
- SGEZKPNUNBVVLB-UHFFFAOYSA-N 5-(chloromethyl)-1,3-dimethylpyrazole Chemical compound CC=1C=C(CCl)N(C)N=1 SGEZKPNUNBVVLB-UHFFFAOYSA-N 0.000 description 26
- NGPWNGKVKQXTBJ-UHFFFAOYSA-N 4-bromo-1-chloro-2-(difluoromethoxy)benzene Chemical compound FC(F)OC1=CC(Br)=CC=C1Cl NGPWNGKVKQXTBJ-UHFFFAOYSA-N 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- 239000012528 membrane Substances 0.000 description 22
- 239000002253 acid Substances 0.000 description 21
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 19
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 125000004429 atom Chemical group 0.000 description 16
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000543 intermediate Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- PZIHQZWEGCWSHF-UHFFFAOYSA-N 5-(chloromethyl)-1h-pyrazole Chemical compound ClCC=1C=CNN=1 PZIHQZWEGCWSHF-UHFFFAOYSA-N 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 239000007983 Tris buffer Substances 0.000 description 13
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 13
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 12
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- CLKLSRDKPNOWAM-UHFFFAOYSA-N 4-(2-chloroethyl)-3,5-dimethyl-1h-pyrazole Chemical compound CC1=NNC(C)=C1CCCl CLKLSRDKPNOWAM-UHFFFAOYSA-N 0.000 description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 229930195712 glutamate Natural products 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 208000010118 dystonia Diseases 0.000 description 8
- 150000002081 enamines Chemical class 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 229960003998 ifenprodil Drugs 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000004471 Glycine Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000014094 Dystonic disease Diseases 0.000 description 6
- 102000034570 NR1 subfamily Human genes 0.000 description 6
- 108020001305 NR1 subfamily Proteins 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000003176 neuroleptic agent Substances 0.000 description 6
- 230000000701 neuroleptic effect Effects 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- GPYMVNVREOOVEQ-UHFFFAOYSA-N 4-(chloromethyl)-1-methylpyrazole Chemical compound CN1C=C(CCl)C=N1 GPYMVNVREOOVEQ-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 4
- CFMBPELVYPUQHV-UHFFFAOYSA-N Cl.CCc1[nH]ncc1CCl Chemical compound Cl.CCc1[nH]ncc1CCl CFMBPELVYPUQHV-UHFFFAOYSA-N 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 4
- 208000012239 Developmental disease Diseases 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 206010036105 Polyneuropathy Diseases 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 230000002964 excitative effect Effects 0.000 description 4
- 239000011737 fluorine Chemical group 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 208000013403 hyperactivity Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000007824 polyneuropathy Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008117 stearic acid Chemical group 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- XGZRBKKGCZKMNK-UHFFFAOYSA-N 3,3-dimethyl-1,2-dihydropyrazole Chemical compound CC1(C=CNN1)C XGZRBKKGCZKMNK-UHFFFAOYSA-N 0.000 description 3
- CFPZDVAZISWERM-UHFFFAOYSA-N 4-bromo-1,2-dichlorobenzene Chemical group ClC1=CC=C(Br)C=C1Cl CFPZDVAZISWERM-UHFFFAOYSA-N 0.000 description 3
- GPGKNEKFDGOXPO-UHFFFAOYSA-N 4-phenyl-1h-pyrazole Chemical compound C1=NNC=C1C1=CC=CC=C1 GPGKNEKFDGOXPO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- JTPIWRBAYVRLAN-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NNC=1)OC(F)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NNC=1)OC(F)F JTPIWRBAYVRLAN-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 102100022645 Glutamate receptor ionotropic, NMDA 1 Human genes 0.000 description 3
- 101710195187 Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 3
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 208000005298 acute pain Diseases 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 208000018300 basal ganglia disease Diseases 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229960002994 dofetilide Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 3
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- ZYCYGSSYUWUVLK-UHFFFAOYSA-N (3-propyl-1H-pyrazol-5-yl)methanol Chemical compound C(CC)C1=CC(=NN1)CO ZYCYGSSYUWUVLK-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- RAQPOZGWANIDQT-UHFFFAOYSA-N 1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine Chemical compound C=1C=CC=CC=1CCCN(CC1)CCN1CCOC(C=1C=CC=CC=1)C1=CC=CC=C1 RAQPOZGWANIDQT-UHFFFAOYSA-N 0.000 description 2
- ZPLZKFHQDARNJQ-UHFFFAOYSA-N 1-methyl-3-[(4-phenylpyrazol-1-yl)methyl]pyrazole Chemical compound CN1N=C(C=C1)CN1N=CC(=C1)C1=CC=CC=C1 ZPLZKFHQDARNJQ-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- AVXQYBVQSTYEEM-UHFFFAOYSA-N 3-(chloromethyl)-1-cyclopentylpyrazole Chemical compound N1=C(CCl)C=CN1C1CCCC1 AVXQYBVQSTYEEM-UHFFFAOYSA-N 0.000 description 2
- KCHJDAKWYFDXAS-UHFFFAOYSA-N 3-(chloromethyl)-1-pentan-3-ylpyrazole Chemical compound CCC(CC)N1C=CC(CCl)=N1 KCHJDAKWYFDXAS-UHFFFAOYSA-N 0.000 description 2
- OOCAUYWXRMOUET-UHFFFAOYSA-N 3-(chloromethyl)-1-propan-2-ylpyrazole Chemical compound CC(C)N1C=CC(CCl)=N1 OOCAUYWXRMOUET-UHFFFAOYSA-N 0.000 description 2
- HTSNFXAICLXZMA-ZDUSSCGKSA-N 3-[(3r)-1-propylpiperidin-3-yl]phenol Chemical compound C1N(CCC)CCC[C@@H]1C1=CC=CC(O)=C1 HTSNFXAICLXZMA-ZDUSSCGKSA-N 0.000 description 2
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 2
- YEXCVPWQMZSECQ-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-1h-pyrazole Chemical compound C1=C(Cl)C(Cl)=CC=C1C1=CNN=C1 YEXCVPWQMZSECQ-UHFFFAOYSA-N 0.000 description 2
- KNSJJZKQRHFLRS-UHFFFAOYSA-N 4-(3,5-difluorophenyl)-1h-pyrazole Chemical compound FC1=CC(F)=CC(C2=CNN=C2)=C1 KNSJJZKQRHFLRS-UHFFFAOYSA-N 0.000 description 2
- NWJALWCDYPLISV-UHFFFAOYSA-N 4-(3-bromophenyl)-1h-pyrazole Chemical compound BrC1=CC=CC(C2=CNN=C2)=C1 NWJALWCDYPLISV-UHFFFAOYSA-N 0.000 description 2
- GCAZXAMCMBEXCC-UHFFFAOYSA-N 4-(4-bromophenyl)-1h-pyrazole Chemical compound C1=CC(Br)=CC=C1C1=CNN=C1 GCAZXAMCMBEXCC-UHFFFAOYSA-N 0.000 description 2
- ULGLRLRMAVGXFW-UHFFFAOYSA-N 4-(4-chlorophenyl)-1h-pyrazole Chemical compound C1=CC(Cl)=CC=C1C1=CNN=C1 ULGLRLRMAVGXFW-UHFFFAOYSA-N 0.000 description 2
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 2
- SLTHMVITKJWPRP-UHFFFAOYSA-N 4-bromo-1-chloro-2-(difluoromethyl)benzene Chemical compound FC(F)C1=CC(Br)=CC=C1Cl SLTHMVITKJWPRP-UHFFFAOYSA-N 0.000 description 2
- YHQZVEGLXIBPRA-UHFFFAOYSA-N 4-bromo-2-(difluoromethyl)-1-fluorobenzene Chemical compound FC(F)C1=CC(Br)=CC=C1F YHQZVEGLXIBPRA-UHFFFAOYSA-N 0.000 description 2
- CJTIWGBQCVYTQE-UHFFFAOYSA-N 4-bromo-2-chloro-1-fluorobenzene Chemical group FC1=CC=C(Br)C=C1Cl CJTIWGBQCVYTQE-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- NKKWKZAXFXJTAX-UHFFFAOYSA-N 5-(chloromethyl)-1-ethylimidazole Chemical compound CCN1C=NC=C1CCl NKKWKZAXFXJTAX-UHFFFAOYSA-N 0.000 description 2
- DPKKRQAEYWOISP-UHFFFAOYSA-N 5-bromo-2-chlorobenzaldehyde Chemical compound ClC1=CC=C(Br)C=C1C=O DPKKRQAEYWOISP-UHFFFAOYSA-N 0.000 description 2
- UEVFFMZHGNYDKM-UHFFFAOYSA-N 5-bromo-2-chlorophenol Chemical group OC1=CC(Br)=CC=C1Cl UEVFFMZHGNYDKM-UHFFFAOYSA-N 0.000 description 2
- MMFGGDVQLQQQRX-UHFFFAOYSA-N 5-bromo-2-fluorobenzaldehyde Chemical compound FC1=CC=C(Br)C=C1C=O MMFGGDVQLQQQRX-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- UAWVRVFHMOSAPU-UHFFFAOYSA-N 7-chlorokynurenic acid Chemical compound C1=CC(Cl)=CC2=NC(C(=O)O)=CC(O)=C21 UAWVRVFHMOSAPU-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- XOPZVFQOFXIGRI-UHFFFAOYSA-N CN1N=C(C=C1)CN1N=CC(=C1)C1=CC=C(C=C1)C(F)(F)F Chemical compound CN1N=C(C=C1)CN1N=CC(=C1)C1=CC=C(C=C1)C(F)(F)F XOPZVFQOFXIGRI-UHFFFAOYSA-N 0.000 description 2
- CJDZRSVYGKAPJM-UHFFFAOYSA-N CN1N=C(C=C1CN1N=CC(=C1)C1=CC(=CC=C1)C(F)(F)F)C Chemical compound CN1N=C(C=C1CN1N=CC(=C1)C1=CC(=CC=C1)C(F)(F)F)C CJDZRSVYGKAPJM-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- VBFITBUPBUWPQS-UHFFFAOYSA-N Cl.Cc1[nH]ncc1CCl Chemical compound Cl.Cc1[nH]ncc1CCl VBFITBUPBUWPQS-UHFFFAOYSA-N 0.000 description 2
- XYGIAPGACDFNDM-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C)F XYGIAPGACDFNDM-UHFFFAOYSA-N 0.000 description 2
- PXLCOAZGYOBHBQ-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C)F Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C)F PXLCOAZGYOBHBQ-UHFFFAOYSA-N 0.000 description 2
- DOLSUXNRMMOQGK-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)C=1C=NN(C=1)CC1=CC(=NN1C)C Chemical compound ClC1=C(C=CC(=C1)Cl)C=1C=NN(C=1)CC1=CC(=NN1C)C DOLSUXNRMMOQGK-UHFFFAOYSA-N 0.000 description 2
- CYBVKIGZLGUYOT-UHFFFAOYSA-N ClC=1C=C(C=CC=1Cl)C=1C=NN(C=1)CC1=CC(=NN1C)C Chemical compound ClC=1C=C(C=CC=1Cl)C=1C=NN(C=1)CC1=CC(=NN1C)C CYBVKIGZLGUYOT-UHFFFAOYSA-N 0.000 description 2
- MWFSWLFIGXOGQC-UHFFFAOYSA-N ClC=1C=C(C=CC=1Cl)C=1C=NN(C=1)CC1=NN(C=C1)C Chemical compound ClC=1C=C(C=CC=1Cl)C=1C=NN(C=1)CC1=NN(C=C1)C MWFSWLFIGXOGQC-UHFFFAOYSA-N 0.000 description 2
- DDHFRTPLOOOEAP-UHFFFAOYSA-N ClC=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=CC(=NN1C)C Chemical compound ClC=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=CC(=NN1C)C DDHFRTPLOOOEAP-UHFFFAOYSA-N 0.000 description 2
- IHSXVSSUCMVPPQ-UHFFFAOYSA-N ClCC1=NNC=C1CC Chemical compound ClCC1=NNC=C1CC IHSXVSSUCMVPPQ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- JUIQWZMUESSJRP-UHFFFAOYSA-N FC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NNC=C1)C Chemical compound FC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NNC=C1)C JUIQWZMUESSJRP-UHFFFAOYSA-N 0.000 description 2
- FOMRZINSAAHONZ-UHFFFAOYSA-N FC=1C=C(C=CC=1C)C=1C=NN(C=1)CC1=CC(=NN1C)C Chemical compound FC=1C=C(C=CC=1C)C=1C=NN(C=1)CC1=CC(=NN1C)C FOMRZINSAAHONZ-UHFFFAOYSA-N 0.000 description 2
- 101150021949 GRIN1 gene Proteins 0.000 description 2
- 101710121995 Glutamate receptor ionotropic, NMDA 1 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 101001034045 Homo sapiens G protein-regulated inducer of neurite outgrowth 2 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 206010043994 Tonic convulsion Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 208000003554 absence epilepsy Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 2
- 208000012601 choreatic disease Diseases 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- WHXXMZCNOHVIDX-UHFFFAOYSA-N ethyl 5-ethyl-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C1=CNN=C1CC WHXXMZCNOHVIDX-UHFFFAOYSA-N 0.000 description 2
- HHYVTIKYZUMDIL-UHFFFAOYSA-N ethyl 5-methyl-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1C HHYVTIKYZUMDIL-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000000848 glutamatergic effect Effects 0.000 description 2
- 239000004220 glutamic acid Chemical group 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000020796 long term synaptic depression Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000003956 synaptic plasticity Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- NAUWTFJOPJWYOT-UHFFFAOYSA-N vanoxerine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)OCCN1CCN(CCCC=2C=CC=CC=2)CC1 NAUWTFJOPJWYOT-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- ISHYFWKKWKXXPL-UHFFFAOYSA-N 1-bromo-2,4-dichlorobenzene Chemical group ClC1=CC=C(Br)C(Cl)=C1 ISHYFWKKWKXXPL-UHFFFAOYSA-N 0.000 description 1
- NCJAJYPBNUFMQK-UHFFFAOYSA-N 1-bromo-3-(1,1-difluoroethyl)benzene Chemical compound CC(F)(F)C1=CC=CC(Br)=C1 NCJAJYPBNUFMQK-UHFFFAOYSA-N 0.000 description 1
- NWBDGKNKAFGQQL-UHFFFAOYSA-N 1-bromo-3-(difluoromethoxy)benzene Chemical compound FC(F)OC1=CC=CC(Br)=C1 NWBDGKNKAFGQQL-UHFFFAOYSA-N 0.000 description 1
- WVUDHWBCPSXAFN-UHFFFAOYSA-N 1-bromo-3-(trifluoromethoxy)benzene Chemical group FC(F)(F)OC1=CC=CC(Br)=C1 WVUDHWBCPSXAFN-UHFFFAOYSA-N 0.000 description 1
- NNMBNYHMJRJUBC-UHFFFAOYSA-N 1-bromo-3-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC=CC(Br)=C1 NNMBNYHMJRJUBC-UHFFFAOYSA-N 0.000 description 1
- BCBNVQYWODLZSI-UHFFFAOYSA-N 1-bromo-3-cyclopropylbenzene Chemical group BrC1=CC=CC(C2CC2)=C1 BCBNVQYWODLZSI-UHFFFAOYSA-N 0.000 description 1
- WBOMXUMQOVQNKT-UHFFFAOYSA-N 1-bromo-3-methylsulfonylbenzene Chemical group CS(=O)(=O)C1=CC=CC(Br)=C1 WBOMXUMQOVQNKT-UHFFFAOYSA-N 0.000 description 1
- XLQSXGGDTHANLN-UHFFFAOYSA-N 1-bromo-4-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC=C(Br)C=C1 XLQSXGGDTHANLN-UHFFFAOYSA-N 0.000 description 1
- KGYXKRGMSUHYCY-UHFFFAOYSA-N 1-bromo-4-fluoro-2-methoxybenzene Chemical group COC1=CC(F)=CC=C1Br KGYXKRGMSUHYCY-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- HLXOVAMYQUFLPE-UHFFFAOYSA-N 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CN1N=CC=C1B1OC(C)(C)C(C)(C)O1 HLXOVAMYQUFLPE-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XUJLWPFSUCHPQL-UHFFFAOYSA-N 11-methyldodecan-1-ol Chemical compound CC(C)CCCCCCCCCCO XUJLWPFSUCHPQL-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- LFHLEABTNIQIQO-UHFFFAOYSA-N 1H-isoindole Chemical compound C1=CC=C2CN=CC2=C1 LFHLEABTNIQIQO-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- PIGNOEXQSXJBGZ-UHFFFAOYSA-N 3,5-bis(chloromethyl)-1h-pyrazol-1-ium;chloride Chemical compound [Cl-].ClCC1=CC(CCl)=N[NH2+]1 PIGNOEXQSXJBGZ-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- ORRXOKMLCURUCL-UHFFFAOYSA-N 3-(chloromethyl)-1-ethylpyrazole;hydrochloride Chemical compound Cl.CCN1C=CC(CCl)=N1 ORRXOKMLCURUCL-UHFFFAOYSA-N 0.000 description 1
- DHOBZYGMEYEAEM-UHFFFAOYSA-N 3-(chloromethyl)-1-methylpyrazole Chemical compound CN1C=CC(CCl)=N1 DHOBZYGMEYEAEM-UHFFFAOYSA-N 0.000 description 1
- VRZMLDYIGISTFM-UHFFFAOYSA-N 3-(chloromethyl)-5-methyl-1h-pyrazole;hydrochloride Chemical compound Cl.CC1=CC(CCl)=NN1 VRZMLDYIGISTFM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JGMGDYUVFBBCEQ-UHFFFAOYSA-N 3-bromo-5-chlorobenzaldehyde Chemical group ClC1=CC(Br)=CC(C=O)=C1 JGMGDYUVFBBCEQ-UHFFFAOYSA-N 0.000 description 1
- GMGWXLPFRHYWAS-UHFFFAOYSA-N 3-bromo-5-chlorophenol Chemical group OC1=CC(Cl)=CC(Br)=C1 GMGWXLPFRHYWAS-UHFFFAOYSA-N 0.000 description 1
- MEFQRXHVMJPOKZ-UHFFFAOYSA-N 3-bromo-5-fluorobenzaldehyde Chemical group FC1=CC(Br)=CC(C=O)=C1 MEFQRXHVMJPOKZ-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- MAGKOTUUZJHLNI-UHFFFAOYSA-N 4-(2-chloroethyl)-1-ethylpyrazole Chemical compound CCN1C=C(CCCl)C=N1 MAGKOTUUZJHLNI-UHFFFAOYSA-N 0.000 description 1
- OAYGXNCRHZTQEB-UHFFFAOYSA-N 4-(2-chloroethyl)-1-methylpyrazole Chemical compound CN1C=C(CCCl)C=N1 OAYGXNCRHZTQEB-UHFFFAOYSA-N 0.000 description 1
- PDBAJMNLLXCMAM-UHFFFAOYSA-N 4-(2-chloroethyl)-1h-pyrazole;hydrochloride Chemical compound Cl.ClCCC=1C=NNC=1 PDBAJMNLLXCMAM-UHFFFAOYSA-N 0.000 description 1
- YIGCJROZILJOGO-UHFFFAOYSA-N 4-(chloromethyl)-1-ethylpyrazole;hydrochloride Chemical compound Cl.CCN1C=C(CCl)C=N1 YIGCJROZILJOGO-UHFFFAOYSA-N 0.000 description 1
- DDGPQOYGZVAPAN-UHFFFAOYSA-N 4-(chloromethyl)-1-methylpyrazole;hydrochloride Chemical compound Cl.CN1C=C(CCl)C=N1 DDGPQOYGZVAPAN-UHFFFAOYSA-N 0.000 description 1
- HSQMRFHDCHGSNZ-UHFFFAOYSA-N 4-(chloromethyl)-5-ethyl-1h-pyrazole Chemical compound CCC=1NN=CC=1CCl HSQMRFHDCHGSNZ-UHFFFAOYSA-N 0.000 description 1
- AMCULCGJPARZBV-UHFFFAOYSA-N 4-[3-(difluoromethoxy)-4-fluorophenyl]-1-[(5-ethyl-1H-pyrazol-4-yl)methyl]pyrazole 2,3-dihydroxybutanedioic acid Chemical compound OC(C(O)C(O)=O)C(O)=O.CCc1[nH]ncc1Cn1cc(cn1)-c1ccc(F)c(OC(F)F)c1 AMCULCGJPARZBV-UHFFFAOYSA-N 0.000 description 1
- XGOCKBMEZPNDPJ-UHFFFAOYSA-N 4-bromo-1-chloro-2-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Br)=CC=C1Cl XGOCKBMEZPNDPJ-UHFFFAOYSA-N 0.000 description 1
- AGYWDGVTLKNTBS-UHFFFAOYSA-N 4-bromo-1-chloro-2-fluorobenzene Chemical group FC1=CC(Br)=CC=C1Cl AGYWDGVTLKNTBS-UHFFFAOYSA-N 0.000 description 1
- OZFQMHJKAODEON-UHFFFAOYSA-N 4-bromo-1-chloro-2-methylbenzene Chemical group CC1=CC(Br)=CC=C1Cl OZFQMHJKAODEON-UHFFFAOYSA-N 0.000 description 1
- VXKYOKPNAXNAFU-UHFFFAOYSA-N 4-bromo-1-fluoro-2-methylbenzene Chemical group CC1=CC(Br)=CC=C1F VXKYOKPNAXNAFU-UHFFFAOYSA-N 0.000 description 1
- VRSBHZMIJMLFDU-UHFFFAOYSA-N 4-bromo-2-(1,1-difluoroethyl)-1-fluorobenzene Chemical group CC(F)(F)C1=CC(Br)=CC=C1F VRSBHZMIJMLFDU-UHFFFAOYSA-N 0.000 description 1
- VIBJPUXLAKVICD-UHFFFAOYSA-N 4-bromo-2-chlorophenol Chemical compound OC1=CC=C(Br)C=C1Cl VIBJPUXLAKVICD-UHFFFAOYSA-N 0.000 description 1
- YZFVUQSAJMLFOZ-UHFFFAOYSA-N 4-bromo-2-fluoro-1-methylbenzene Chemical group CC1=CC=C(Br)C=C1F YZFVUQSAJMLFOZ-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- VGPBRGSCQLQISU-UHFFFAOYSA-N 5-(2-chloroethyl)-1-ethylpyrazole Chemical compound CCN1N=CC=C1CCCl VGPBRGSCQLQISU-UHFFFAOYSA-N 0.000 description 1
- AZJCOEIXXHKICT-UHFFFAOYSA-N 5-(2-chloroethyl)-1-methylpyrazole Chemical compound CN1N=CC=C1CCCl AZJCOEIXXHKICT-UHFFFAOYSA-N 0.000 description 1
- KWLOIDOKWUESNM-UHFFFAOYSA-N 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NN1 KWLOIDOKWUESNM-UHFFFAOYSA-N 0.000 description 1
- VJSNQQPMQRHJPE-UHFFFAOYSA-N 5-(chloromethyl)-1-ethylpyrazole;hydrochloride Chemical compound Cl.CCN1N=CC=C1CCl VJSNQQPMQRHJPE-UHFFFAOYSA-N 0.000 description 1
- DMALVWVARIVUJD-UHFFFAOYSA-N 5-(chloromethyl)-1-methylpyrazole Chemical compound CN1N=CC=C1CCl DMALVWVARIVUJD-UHFFFAOYSA-N 0.000 description 1
- IPKKDQOUBFUVGT-UHFFFAOYSA-N 5-(chloromethyl)-1h-pyrazole;hydrochloride Chemical compound Cl.ClCC=1C=CNN=1 IPKKDQOUBFUVGT-UHFFFAOYSA-N 0.000 description 1
- YPTHSYKJDRMAJY-UHFFFAOYSA-N 5-bromo-2-fluorophenol Chemical group OC1=CC(Br)=CC=C1F YPTHSYKJDRMAJY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010061660 Artery dissection Diseases 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- WTIFREIJFMTPOT-UHFFFAOYSA-N C1(CC1)C=1C=C(C=CC=1)C=1C=NN(C=1)CC1=NNC=C1 Chemical compound C1(CC1)C=1C=C(C=CC=1)C=1C=NN(C=1)CC1=NNC=C1 WTIFREIJFMTPOT-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- WMUAUDVHENODTB-UHFFFAOYSA-N CN1N=CC(=C1)CN1N=CC(=C1)C1=CC(=CC=C1)S(=O)(=O)C Chemical compound CN1N=CC(=C1)CN1N=CC(=C1)C1=CC(=CC=C1)S(=O)(=O)C WMUAUDVHENODTB-UHFFFAOYSA-N 0.000 description 1
- RAFYHYBKKVGIIK-UHFFFAOYSA-N CS(=O)(=O)C=1C=C(C=CC=1)C=1C=NN(C=1)CC1=NNC=C1 Chemical compound CS(=O)(=O)C=1C=C(C=CC=1)C=1C=NN(C=1)CC1=NNC=C1 RAFYHYBKKVGIIK-UHFFFAOYSA-N 0.000 description 1
- 238000003148 Calcium 5 Assay Kit Methods 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 201000001913 Childhood absence epilepsy Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- QQAYZGOBUDZJCX-UHFFFAOYSA-N Cl.CCCc1cc(CCl)[nH]n1 Chemical compound Cl.CCCc1cc(CCl)[nH]n1 QQAYZGOBUDZJCX-UHFFFAOYSA-N 0.000 description 1
- MAUHYLGKOSWYHW-UHFFFAOYSA-N Cl.CCc1cc(CCl)[nH]n1 Chemical compound Cl.CCc1cc(CCl)[nH]n1 MAUHYLGKOSWYHW-UHFFFAOYSA-N 0.000 description 1
- NVPPRZHNQAGZNI-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C)C Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C)C NVPPRZHNQAGZNI-UHFFFAOYSA-N 0.000 description 1
- AENUUQTUDHOBSJ-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C)C Chemical compound ClC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C)C AENUUQTUDHOBSJ-UHFFFAOYSA-N 0.000 description 1
- WVXIDDGREBYPIF-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)C=1C=NN(C=1)CC1=NN(C=C1)C Chemical compound ClC1=C(C=CC(=C1)Cl)C=1C=NN(C=1)CC1=NN(C=C1)C WVXIDDGREBYPIF-UHFFFAOYSA-N 0.000 description 1
- PVABBWISXQDWEN-UHFFFAOYSA-N ClC=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NN(C=C1)C Chemical compound ClC=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NN(C=C1)C PVABBWISXQDWEN-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000032065 Convulsion neonatal Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012676 Diabetic mononeuropathy Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 206010073681 Epidural haemorrhage Diseases 0.000 description 1
- 208000024658 Epilepsy syndrome Diseases 0.000 description 1
- 208000002877 Epileptic Syndromes Diseases 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- IDFCRAJKFUCDED-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NNC(=C1)CC)F Chemical compound FC(C=1C=C(C=CC=1F)C=1C=NN(C=1)CC1=NNC(=C1)CC)F IDFCRAJKFUCDED-UHFFFAOYSA-N 0.000 description 1
- BWVRPGYKZYASIH-UHFFFAOYSA-N FC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C)C Chemical compound FC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C)C BWVRPGYKZYASIH-UHFFFAOYSA-N 0.000 description 1
- NTXJOFGNCFFNLA-UHFFFAOYSA-N FC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CN=CN1CC)C Chemical compound FC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=CN=CN1CC)C NTXJOFGNCFFNLA-UHFFFAOYSA-N 0.000 description 1
- OPNJBKUMFOXMHL-UHFFFAOYSA-N FC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C)C Chemical compound FC1=C(C=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C)C OPNJBKUMFOXMHL-UHFFFAOYSA-N 0.000 description 1
- UYFOFEJPPDSOCE-UHFFFAOYSA-N FC1=CC(=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C)OC Chemical compound FC1=CC(=C(C=C1)C=1C=NN(C=1)CC1=CC(=NN1C)C)OC UYFOFEJPPDSOCE-UHFFFAOYSA-N 0.000 description 1
- MSGIBHWJHGBUEJ-UHFFFAOYSA-N FC1=CC(=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C)OC Chemical compound FC1=CC(=C(C=C1)C=1C=NN(C=1)CC1=NN(C=C1)C)OC MSGIBHWJHGBUEJ-UHFFFAOYSA-N 0.000 description 1
- KUEVFLYYENSXRM-UHFFFAOYSA-N FC=1C=C(C=CC=1C)C=1C=NN(C=1)CC1=CC=NN1C Chemical compound FC=1C=C(C=CC=1C)C=1C=NN(C=1)CC1=CC=NN1C KUEVFLYYENSXRM-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 101710150822 G protein-regulated inducer of neurite outgrowth 1 Proteins 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102100038942 Glutamate receptor ionotropic, NMDA 3A Human genes 0.000 description 1
- 101710195181 Glutamate receptor ionotropic, NMDA 3A Proteins 0.000 description 1
- 102100038958 Glutamate receptor ionotropic, NMDA 3B Human genes 0.000 description 1
- 101710195174 Glutamate receptor ionotropic, NMDA 3B Proteins 0.000 description 1
- 101100404734 Glycine max INR1 gene Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000972850 Homo sapiens Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 description 1
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021030 Hypomania Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
- 102000000079 Kainic Acid Receptors Human genes 0.000 description 1
- 108010069902 Kainic Acid Receptors Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KKVUHGSKZUFHIU-UHFFFAOYSA-N OC(=O)CCC(O)=O.C(c1ccn[nH]1)n1cc(cn1)-c1cccc(c1)C1CC1 Chemical compound OC(=O)CCC(O)=O.C(c1ccn[nH]1)n1cc(cn1)-c1cccc(c1)C1CC1 KKVUHGSKZUFHIU-UHFFFAOYSA-N 0.000 description 1
- GPPOYSKPALOXIX-UHFFFAOYSA-N OC(=O)CCC(O)=O.CCc1cn[nH]c1Cn1cc(cn1)-c1ccc(F)c(OC(F)F)c1 Chemical compound OC(=O)CCC(O)=O.CCc1cn[nH]c1Cn1cc(cn1)-c1ccc(F)c(OC(F)F)c1 GPPOYSKPALOXIX-UHFFFAOYSA-N 0.000 description 1
- VMRHXQWFBPYAOI-UHFFFAOYSA-N OC(=O)CCC(O)=O.COc1cc(F)ccc1-c1cnn(Cc2cc(C)nn2C)c1 Chemical compound OC(=O)CCC(O)=O.COc1cc(F)ccc1-c1cnn(Cc2cc(C)nn2C)c1 VMRHXQWFBPYAOI-UHFFFAOYSA-N 0.000 description 1
- OKZNVSXHRBNAOH-UHFFFAOYSA-N OC(=O)CCC(O)=O.COc1cc(F)ccc1-c1cnn(Cc2ccn(C)n2)c1 Chemical compound OC(=O)CCC(O)=O.COc1cc(F)ccc1-c1cnn(Cc2ccn(C)n2)c1 OKZNVSXHRBNAOH-UHFFFAOYSA-N 0.000 description 1
- WUFPMJYLSYMWCH-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cc1cc(Cn2cc(cn2)-c2ccc(Cl)c(C)c2)n(C)n1 Chemical compound OC(=O)CCC(O)=O.Cc1cc(Cn2cc(cn2)-c2ccc(Cl)c(C)c2)n(C)n1 WUFPMJYLSYMWCH-UHFFFAOYSA-N 0.000 description 1
- VEOZGXCJWCGIQG-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cc1cc(Cn2cc(cn2)-c2ccc(Cl)c(c2)C(F)(F)F)n(C)n1 Chemical compound OC(=O)CCC(O)=O.Cc1cc(Cn2cc(cn2)-c2ccc(Cl)c(c2)C(F)(F)F)n(C)n1 VEOZGXCJWCGIQG-UHFFFAOYSA-N 0.000 description 1
- HJWJSQMJFOSDCE-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cc1cc(Cn2cc(cn2)-c2ccc(F)c(C)c2)n(C)n1 Chemical compound OC(=O)CCC(O)=O.Cc1cc(Cn2cc(cn2)-c2ccc(F)c(C)c2)n(C)n1 HJWJSQMJFOSDCE-UHFFFAOYSA-N 0.000 description 1
- CJFNDULDWRBNAN-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cc1cc(Cn2cc(cn2)-c2cccc(Br)c2)n(C)n1 Chemical compound OC(=O)CCC(O)=O.Cc1cc(Cn2cc(cn2)-c2cccc(Br)c2)n(C)n1 CJFNDULDWRBNAN-UHFFFAOYSA-N 0.000 description 1
- MIHVDDPFZDSPSE-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cc1cc(Cn2cc(cn2)-c2ccccn2)n(C)n1 Chemical compound OC(=O)CCC(O)=O.Cc1cc(Cn2cc(cn2)-c2ccccn2)n(C)n1 MIHVDDPFZDSPSE-UHFFFAOYSA-N 0.000 description 1
- GFIMTUXZIJYTCT-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cc1cc(ccc1Cl)-c1cnn(Cc2ccn(C)n2)c1 Chemical compound OC(=O)CCC(O)=O.Cc1cc(ccc1Cl)-c1cnn(Cc2ccn(C)n2)c1 GFIMTUXZIJYTCT-UHFFFAOYSA-N 0.000 description 1
- XMKUUGHVGNVMOS-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cc1cc(ccc1F)-c1cnn(Cc2ccn(C)n2)c1 Chemical compound OC(=O)CCC(O)=O.Cc1cc(ccc1F)-c1cnn(Cc2ccn(C)n2)c1 XMKUUGHVGNVMOS-UHFFFAOYSA-N 0.000 description 1
- OCMVBXZHEHKIOR-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cc1ccc(cc1F)-c1cnn(Cc2ccn(C)n2)c1 Chemical compound OC(=O)CCC(O)=O.Cc1ccc(cc1F)-c1cnn(Cc2ccn(C)n2)c1 OCMVBXZHEHKIOR-UHFFFAOYSA-N 0.000 description 1
- NRIFKKMZECMFRN-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cn1cc(Cn2cc(cn2)-c2ccc(F)c(c2)C(C)(F)F)cn1 Chemical compound OC(=O)CCC(O)=O.Cn1cc(Cn2cc(cn2)-c2ccc(F)c(c2)C(C)(F)F)cn1 NRIFKKMZECMFRN-UHFFFAOYSA-N 0.000 description 1
- SDSOAJCFZKBLNO-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cn1cc(Cn2cc(cn2)-c2cccc(c2)S(C)(=O)=O)cn1 Chemical compound OC(=O)CCC(O)=O.Cn1cc(Cn2cc(cn2)-c2cccc(c2)S(C)(=O)=O)cn1 SDSOAJCFZKBLNO-UHFFFAOYSA-N 0.000 description 1
- QKIWUAQLAZAJEW-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cn1ccc(Cn2cc(cn2)-c2ccc(Cl)cc2Cl)n1 Chemical compound OC(=O)CCC(O)=O.Cn1ccc(Cn2cc(cn2)-c2ccc(Cl)cc2Cl)n1 QKIWUAQLAZAJEW-UHFFFAOYSA-N 0.000 description 1
- LSZLSQKSWCIPRF-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cn1ccc(Cn2cc(cn2)-c2ccc(F)c(Cl)c2)n1 Chemical compound OC(=O)CCC(O)=O.Cn1ccc(Cn2cc(cn2)-c2ccc(F)c(Cl)c2)n1 LSZLSQKSWCIPRF-UHFFFAOYSA-N 0.000 description 1
- AZGGJEVCWOGQRU-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cn1ccc(Cn2cc(cn2)-c2ccc(F)c(c2)C(F)F)n1 Chemical compound OC(=O)CCC(O)=O.Cn1ccc(Cn2cc(cn2)-c2ccc(F)c(c2)C(F)F)n1 AZGGJEVCWOGQRU-UHFFFAOYSA-N 0.000 description 1
- XFFHQAIHVTXWRK-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cn1ccc(Cn2cc(cn2)-c2cccc(Br)c2)n1 Chemical compound OC(=O)CCC(O)=O.Cn1ccc(Cn2cc(cn2)-c2cccc(Br)c2)n1 XFFHQAIHVTXWRK-UHFFFAOYSA-N 0.000 description 1
- YXRWJQPAVAGLQE-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cn1ccc(Cn2cc(cn2)-c2cccc(c2)C(F)(F)F)n1 Chemical compound OC(=O)CCC(O)=O.Cn1ccc(Cn2cc(cn2)-c2cccc(c2)C(F)(F)F)n1 YXRWJQPAVAGLQE-UHFFFAOYSA-N 0.000 description 1
- GZCFFJSDUGQPLA-UHFFFAOYSA-N OC(=O)CCC(O)=O.Cn1ccc(Cn2cc(cn2)-c2ccccn2)n1 Chemical compound OC(=O)CCC(O)=O.Cn1ccc(Cn2cc(cn2)-c2ccccn2)n1 GZCFFJSDUGQPLA-UHFFFAOYSA-N 0.000 description 1
- FHTZFIRLKFWNBY-BTJKTKAUSA-N OC(=O)\C=C/C(O)=O.CC(F)(F)c1cccc(c1)-c1cnn(Cc2ccn[nH]2)c1 Chemical compound OC(=O)\C=C/C(O)=O.CC(F)(F)c1cccc(c1)-c1cnn(Cc2ccn[nH]2)c1 FHTZFIRLKFWNBY-BTJKTKAUSA-N 0.000 description 1
- BZAYPLGTIPHZDS-BTJKTKAUSA-N OC(=O)\C=C/C(O)=O.FC(F)Oc1cccc(c1)-c1cnn(Cc2ccn[nH]2)c1 Chemical compound OC(=O)\C=C/C(O)=O.FC(F)Oc1cccc(c1)-c1cnn(Cc2ccn[nH]2)c1 BZAYPLGTIPHZDS-BTJKTKAUSA-N 0.000 description 1
- GQCLZSNFOMJNEZ-UHFFFAOYSA-N OC(C(O)C(O)=O)C(O)=O.CCc1[nH]ncc1Cn1cc(cn1)-c1ccc(F)c(c1)C(C)(F)F Chemical compound OC(C(O)C(O)=O)C(O)=O.CCc1[nH]ncc1Cn1cc(cn1)-c1ccc(F)c(c1)C(C)(F)F GQCLZSNFOMJNEZ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 206010042364 Subdural haemorrhage Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 240000000278 Syzygium polyanthum Species 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 208000009158 Traumatic Intracranial Hemorrhage Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- 208000013142 Writer cramp Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229960002629 agomelatine Drugs 0.000 description 1
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- RFGYFJNXGDBYDR-UHFFFAOYSA-N butanedioic acid 1,3-dimethyl-5-[[4-[3-(trifluoromethoxy)phenyl]pyrazol-1-yl]methyl]pyrazole Chemical compound OC(=O)CCC(O)=O.Cc1cc(Cn2cc(cn2)-c2cccc(OC(F)(F)F)c2)n(C)n1 RFGYFJNXGDBYDR-UHFFFAOYSA-N 0.000 description 1
- HHWNDDQPZINLHF-UHFFFAOYSA-N butanedioic acid 1-methyl-3-[[4-[3-(trifluoromethoxy)phenyl]pyrazol-1-yl]methyl]pyrazole Chemical compound OC(=O)CCC(O)=O.Cn1ccc(Cn2cc(cn2)-c2cccc(OC(F)(F)F)c2)n1 HHWNDDQPZINLHF-UHFFFAOYSA-N 0.000 description 1
- ASUPHFYLQUTEDM-UHFFFAOYSA-N butanedioic acid 4-(3-methylsulfonylphenyl)-1-(1H-pyrazol-5-ylmethyl)pyrazole Chemical compound OC(=O)CCC(O)=O.CS(=O)(=O)c1cccc(c1)-c1cnn(Cc2ccn[nH]2)c1 ASUPHFYLQUTEDM-UHFFFAOYSA-N 0.000 description 1
- CZOFMWNHWCDRFZ-UHFFFAOYSA-N butanedioic acid 4-[2-[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]ethyl]-3,5-dimethyl-1H-pyrazole Chemical compound OC(=O)CCC(O)=O.Cc1n[nH]c(C)c1CCn1cc(cn1)-c1ccc(Cl)c(OC(F)F)c1 CZOFMWNHWCDRFZ-UHFFFAOYSA-N 0.000 description 1
- JNRZDGVWNLFBCV-UHFFFAOYSA-N butanedioic acid 4-[3-(1,1-difluoroethyl)-4-fluorophenyl]-1-(1H-pyrazol-5-ylmethyl)pyrazole Chemical compound OC(=O)CCC(O)=O.CC(F)(F)c1cc(ccc1F)-c1cnn(Cc2ccn[nH]2)c1 JNRZDGVWNLFBCV-UHFFFAOYSA-N 0.000 description 1
- VSSPUVFXWPPDPJ-UHFFFAOYSA-N butanedioic acid 4-[3-(difluoromethyl)-5-fluorophenyl]-1-(1H-pyrazol-5-ylmethyl)pyrazole Chemical compound OC(=O)CCC(O)=O.FC(F)c1cc(F)cc(c1)-c1cnn(Cc2ccn[nH]2)c1 VSSPUVFXWPPDPJ-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 206010008087 cerebral arteritis Diseases 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000006726 chronic neurodegeneration Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000002342 diabetic polyneuropathy Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 229960002380 dibutyl phthalate Drugs 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical group CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical compound CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- UDRCONFHWYGWFI-UHFFFAOYSA-N ethyl 3-oxopentanoate Chemical compound CCOC(=O)CC(=O)CC UDRCONFHWYGWFI-UHFFFAOYSA-N 0.000 description 1
- SUALHSUMUQQLJP-UHFFFAOYSA-N ethyl 5-propyl-1h-pyrazole-3-carboxylate Chemical compound CCCC1=CC(C(=O)OCC)=NN1 SUALHSUMUQQLJP-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 201000002865 focal hand dystonia Diseases 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000009939 hypertensive encephalopathy Diseases 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000002151 myoclonic effect Effects 0.000 description 1
- 208000028492 myoclonic seizure Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000037860 neuroleptic-induced Akathisia Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- VLZLOWPYUQHHCG-UHFFFAOYSA-N nitromethylbenzene Chemical compound [O-][N+](=O)CC1=CC=CC=C1 VLZLOWPYUQHHCG-UHFFFAOYSA-N 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical class CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 208000007771 sciatic neuropathy Diseases 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000002899 segmental dystonia Diseases 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- MRTAVLDNYYEJHK-UHFFFAOYSA-M sodium;2-chloro-2,2-difluoroacetate Chemical compound [Na+].[O-]C(=O)C(F)(F)Cl MRTAVLDNYYEJHK-UHFFFAOYSA-M 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 208000018724 torsion dystonia Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Description
本出願は、2015年4月13日に出願された米国特許仮出願第62/146,629号及び2014年8月15日に出願された米国特許仮出願第62/037,815号に対する優先権を主張するものであり、これらの出願の全内容は本明細書において参照により援用されている。
本発明は、ピラゾール誘導体、並びに様々な疾病及び病気の治療を目的とした、それらピラゾール誘導体の化合物の使用に関する。
本発明は、とりわけ、式(I):
n=1又は2であり、
Hetは、
R1及びR2は、各々独立に、水素;F、Cl、Brから選択されるハロゲン;直鎖状又は分枝状で、少なくとも1つの置換基、例えば、ヒドロキシ、ハロゲンから選択される1つ、2つ又は3つの置換基で任意選択的に置換された、C1〜6アルキル;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルコキシ;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C3〜6シクロアルキル;ヒドロキシ、ハロゲンから選択される少なくとも1つの置換基、例えば、1つ、2つ又は3つの置換基で任意選択的に置換された、C3〜6シクロアルキル;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルキル;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルコキシ;少なくとも1つの置換基、例えば、ヒドロキシ、ハロゲンから選択される1つ、2つ又は3つの置換基で任意選択的に置換された、C1〜6アルコキシ;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルコキシ;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C3〜6シクロアルキル;少なくとも1つの置換基、例えば、ヒドロキシ、ハロゲンから選択される1つ、2つ又は3つの置換基で任意選択的に置換された、−O−C3〜6シクロアルキル;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルキル;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルコキシ;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、−S−C1〜3アルキル;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、−SO2−C1〜3アルキル;及び−SF5から選択され;あるいは
R1及びR2は一緒になって、少なくとも1つの置換基、例えば、ヒドロキシ;ハロゲン;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルキル;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で置換された、C1〜3アルコキシ、から選択される1つ、2つ、3つ、4つ又は5つの置換基で任意選択的に置換された、5〜7員の炭素環式化合物;又はO、S又はNであり得る1〜3つのヘテロ原子を含有し、少なくとも1つの置換基、例えば、ヒドロキシ;ハロゲン;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルキル;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で置換された、C1〜3アルコキシから選択される1つ、2つ、3つ、4つ又は5つの置換基で任意選択的に置換された、5〜7員の複素環を形成し、
R3及びR4は、各々独立に、水素;ハロゲン;及び直鎖状又は分枝状で、少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜5アルキルから選択され;但し、R3及びR4の少なくとも1つは、水素を表すことを条件とし;
R5及びR6は、各々独立に、水素;ハロゲン;C1〜6アルキルアミノ及びジ(C1〜6アルキル)アミノをはじめとするアミノ;直鎖状又は分枝状で、ハロゲン、ヒドロキシから選択される少なくとも1つの置換基、例えば、1つ、2つ又は3つの置換基で任意選択的に置換された、C1〜5アルキル;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルコキシ;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C3〜6シクロアルキル;直鎖状又は分枝状で、少なくとも1つの置換基、例えば、ヒドロキシ、ハロゲンから選択される1つ、2つ又は3つの置換基で任意選択的に置換された、C1〜5アルコキシ;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルコキシ;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C3〜6シクロアルキル;及び少なくとも1つの置換基、例えば、ヒドロキシ、ハロゲンから選択される1つ、2つ又は3つの置換基で任意選択的に置換された、C3〜6シクロアルキル;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルキル;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で置換された、C1〜3アルコキシから選択され;かつ
R7は、水素;直鎖状又は分枝状で、少なくとも1つの置換基、例えば、ハロゲン、ヒドロキシから選択される1つ、2つ又は3つの置換基で任意選択的に置換された、C1〜5アルキル;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルコキシ;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C3〜6シクロアルキル;及び少なくとも1つの置換基、例えば、ヒドロキシ、ハロゲンから選択される1つ、2つ又は3つの置換基で任意選択的に置換された、C3〜6シクロアルキル;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルキル;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で置換された、C1〜3アルコキシから選択される。
R5及びR6は、各々独立に、水素;F;Cl;アミノ;直鎖状又は分枝状で、ハロゲン原子、ヒドロキシから選択される少なくとも1つの置換基、例えば、1つ、2つ又は3つの置換基で任意選択的に置換された、C1〜3アルキル;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルコキシ;例えば、メチル、エチル、n−プロピル、i−プロピル;直鎖状又は分枝状で、少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルコキシ;例えば、メトキシ;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C3〜6シクロアルキル;例えば、シクロプロピル、シクロブチル、シクロペンチル;並びに少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C3〜6シクロアルキル−C1〜3アルキル;例えば、シクロプロピルメチルから選択され;かつ
R7は、水素;直鎖状又は分枝状で、ハロゲン、ヒドロキシから選択される少なくとも1つの置換基、例えば、1つ、2つ又は3つの置換基で任意選択的に置換された、C1〜3アルキル;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルコキシ;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C3〜6シクロアルキル;例えば、メチル、エチル、n−プロピル、i−プロピル、シクロプロピルメチル;あるいは、少なくとも1つの置換基、例えば、ヒドロキシ、ハロゲンから選択される1つ、2つ又は3つの置換基で任意選択的に置換された、C3〜6シクロアルキル;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルキル;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で置換された、C1〜3アルコキシ;例えば、シクロプロピル、シクロブチル、シクロペンチルである。
R3及びR4は、各々独立に水素、F、及びClから選択され、但し、R3及びR4の少なくとも1つが水素を表すことを条件とし;
R5及びR6は、各々独立に、水素;アミノ;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルキル;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C3〜6シクロアルキル;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C3〜6シクロアルキル−C1〜3アルキルから選択され;かつ
R7は、水素;直鎖状又は分枝状で、ハロゲン、ヒドロキシから選択される少なくとも1つの置換基、例えば、1つ、2つ又は3つの置換基で任意選択的に置換された、C1〜3アルキル;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルコキシ;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C3〜6シクロアルキル;例えば、メチル、エチル、n−プロピル、i−プロピル;及び少なくとも1つの置換基、例えば、ヒドロキシ、ハロゲンから選択される1つ、2つ又は3つの置換基で任意選択的に置換された、C3〜6シクロアルキル;少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で任意選択的に置換された、C1〜3アルキル;及び少なくとも1つのハロゲン原子、例えば、1つ、2つ又は3つのハロゲン原子で置換された、C1〜3アルコキシ;例えば、シクロプロピル、シクロブチル、シクロペンチルから選択される。
■ 4−[2−[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]エチル]−3,5−ジメチル−1H−ピラゾール、
■ 3−[[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]−1−メチルピラゾール、
■ 5−[[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−[(1−メチルピラゾール−4−イル)メチル]ピラゾール、
■ 4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−[(2−メチルピラゾール−3−イル)メチル]ピラゾール、
■ 4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
■ 4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−(1H−ピラゾール−4−イルメチル)ピラゾール、
■ 3−[[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]−1−エチルピラゾール、
■ 4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−[2−(1H−ピラゾール−4−イル)エチル]ピラゾール、
■ 4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−[2−(1−エチルピラゾール−4−イル)エチル]ピラゾール、
■ 3−[[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]−1−(1−エチルプロピル)−ピラゾール、
■ 3−[[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]−1−シクロペンチル−ピラゾール、
■ 4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−[(3−メチル−1H−ピラゾール−5−イル)メチル]ピラゾール、
■ 3−[[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]−5−エチル−1H−ピラゾール、
■ 3−[[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]−5−プロピル−1H−ピラゾール、
■ 4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−[(5−メチル−1H−ピラゾール−4−イル)メチル]ピラゾール、
■ 4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−[(5−エチル−1H−ピラゾール−4−イル)メチル]ピラゾール、
■ 4−[3−(ジフルオロメトキシ)−4−フルオロ−フェニル]−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
■ 4−[3−(ジフルオロメトキシ)−4−フルオロ−フェニル]−1−[(1メチルピラゾール−4−イル)メチル]ピラゾール、
■ 4−[3−クロロ−5−(ジフルオロメトキシ)フェニル]−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
■ 1,3−ジメチル−5−[[4−[3−(トリフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]ピラゾール、
■ 1−メチル−3−[[4−[3−(トリフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]ピラゾール、
■ 3−[[4−[4−クロロ−3−(ジフルオロメチル)フェニル]ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 5−[[4−[4−クロロ−3−(ジフルオロメチル)フェニル]ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 4−[4−クロロ−3−(ジフルオロメチル)フェニル]−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
■ 4−[2−[4−[4−クロロ−3−(ジフルオロメチル)フェニル]ピラゾール−1−イル]エチル]−3,5−ジメチル−1H−ピラゾール、
■ 4−[3−クロロ−5−(ジフルオロメチル)フェニル]−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
■ 5−[[4−[4−クロロ−3−(トリフルオロメチル)フェニル]ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 3−[[4−[4−クロロ−3−(トリフルオロメチル)フェニル]ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 3−[[4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 5−[[4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]−1−[(1−メチルピラゾール−4−イル)メチル]ピラゾール、
■ 4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]−1−[(2−メチルピラゾール−3−イル)メチル]ピラゾール、
■ 4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]−1−(1H−ピラゾール−3−イルメチル)ピラゾール、
■ 4−[2−[4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]ピラゾール−1−イル]エチル]−3,5−ジメチル−1H−ピラゾール、
■ 4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]−1−[2−(1H−ピラゾール−4−イル)エチル]ピラゾール、
■ 3−[[4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]ピラゾール−1−イル]メチル]−1−エチル−ピラゾール、
■ 4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]−1−[(3−メチル−1H−ピラゾール−5−イル)メチル]ピラゾール、
■ 3−[[4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]ピラゾール−1−イル]メチル]−5−エチル−1H−ピラゾール、
■ 3−[[4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]ピラゾール−1−イル]メチル]−5−プロピル−1H−ピラゾール、
■ 4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]−1−[(5−メチル−1H−ピラゾール−4−イル)メチル]ピラゾール、
■ 4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]−1−[(5−エチル−1H−ピラゾール−4−イル)メチル]ピラゾール、
■ 4−[3−(1,1−ジフルオロエチル)−4−フルオロ−フェニル]−1−(1H−ピラゾール−3−イルメチル)ピラゾール、
■ 4−[3−(1,1−ジフルオロエチル)−4−フルオロ−フェニル]−1−[(1−メチルピラゾール−4−イル)メチル]ピラゾール、
■ 4−[3−(1,1−ジフルオロエチル)−4−フルオロ−フェニル]−1−[(5−エチル−1H−ピラゾール−4−イル)メチル]ピラゾール、
■ 4−[3−(ジフルオロメチル)−5−フルオロ−フェニル]−1−[2−(1H−ピラゾール−3−イルメチル]ピラゾール、
■ 1,3−ジメチル−5−[[4−[3−(トリフルオロメチル)フェニル]ピラゾール−1−イル]メチル]ピラゾール、
■ 1−メチル−3−[[4−[3−(トリフルオロメチル)フェニル]ピラゾール−1−イル]メチル]ピラゾール、
■ 1−メチル−3−[[4−[4−(トリフルオロメチル)フェニル]ピラゾール−1−イル]メチル]ピラゾール、
■ 1,3−ジメチル−5−[[4−[4−(トリフルオロメチル)フェニル]ピラゾール−1−イル]メチル]ピラゾール、
■ 5−[[4−(3−フルオロ−4−メチル−フェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 5−[[4−(3−フルオロ−4−メチル−フェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 5−[[4−(4−フルオロ−3−メチル−フェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 3−[[4−(4−フルオロ−3−メチル−フェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 4−(4−フルオロ−3−メチル−フェニル)−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
■ 5−[[4−(4−クロロ−3−メチル−フェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 3−[[4−(4−クロロ−3−メチル−フェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 3−[[4−(4−クロロ−3−フルオロ−フェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 5−[[4−(4−クロロ−3−フルオロ−フェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 3−[[4−(3−クロロ−4−フルオロ−フェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 5−[[4−(3−クロロ−4−フルオロ−フェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 3−[[4−(3,4−ジクロロフェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 5−[[4−(3,4−ジクロロフェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 5−[[4−(2,4−ジクロロフェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 3−[[4−(2,4−ジクロロフェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 3−[[4−(4−フルオロ−2−メトキシ−フェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 5−[[4−(4−フルオロ−2−メトキシ−フェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 4−(3−シクロプロピルフェニル)−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
■ 4−(3−メチルスルホニルフェニル)−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
■ 1−メチル−4−[[4−(3−メチルスルホニルフェニル)ピラゾール−1−イル]メチル]−ピラゾール、
■ ペンタフルオロ−[3−[1−(1H−ピラゾール−3−イルメチル)ピラゾール−4−イル]]フェニル]−スルファン、
■ 4−[2−[4−(4−クロロフェニル)−ピラゾール−1−イル]エチル]−3,5−ジメチル−1H−ピラゾール、
■ 5−[[4−(4−クロロフェニル)−ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 3−[[4−(4−クロロフェニル)−ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 4−(4−クロロフェニル)−1−[(2−メチルピラゾール−3−イル)メチル]ピラゾール、
■ 4−(4−クロロフェニル)−1−(1H−ピラゾール−3−イルメチル)ピラゾール、
■ 4−(4−クロロフェニル)−1−[(1−メチルピラゾール−4−イル)メチル]ピラゾール、
■ 3−[[4−(4−ブロモフェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 5−[[4−(4−ブロモフェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 5−[[4−(3−ブロモフェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 3−[[4−(3−ブロモフェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 5−[[4−(3,5−ジフルオロフェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
■ 3−[[4−(3,5−ジフルオロフェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
■ 1−メチル−3−[(4−フェニルピラゾール−1−イル)メチル]ピラゾール、
■ 1,3−ジメチル−5−[(4−フェニルピラゾール−1−イル)メチル]ピラゾール、
■ 1−メチル−5−[(4−フェニルピラゾール−1−イル)メチル]ピラゾール、
■ 4−[[4−(3−ジフルオロメトキシ−4−クロロ−フェニル)ピラゾール−1−イル]メチル]−3,5−ジメチル−1H−ピラゾール、
■ 4−[[4−(3−ジフルオロメチル−4−フルオロ−フェニル)ピラゾール−1−イル]メチル]−3,5−ジメチル−1H−ピラゾール、
■ 4−[[4−(3−(1,1−ジフルオロエチル−4−フルオロ−フェニル)ピラゾール−1−イル]メチル]−3,5−ジメチル−1H−ピラゾール、
■ 3−[[4−[3−(ジフルオロメトキシ)−4−フルオロ−フェニル]ピラゾール−1−イル]メチル]−4−エチル−1H−ピラゾール、
■ 3−[[4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]ピラゾール−1−イル]メチル]−4−エチル−1H−ピラゾール、
■ 3−[[4−(3−(1,1−ジフルオロエチル)−フェニル)ピラゾール−1−イル]メチル]−1H−ピラゾール(マレイン酸塩として)、及び
■ 3−[[4−(3−(ジフルオロメトキシ)−フェニル)ピラゾール−1−イル]メチル]−1H−ピラゾール(マレイン酸塩として)である。
用語「アルキル」とは、鎖内に1〜12個の炭素原子を有する直鎖若しくは分枝鎖アルキル基を指す。幾つかの実施形態において、アルキル基は、C1〜C6アルキル基である。幾つかの実施形態において、アルキル基は、C1〜C4アルキル基である。アルキル基の例としては、メチル(Me)、エチル(Et)、n−プロピル、イソプロピル、ブチル、イソブチル、sec−ブチル、tert−ブチル(tBu)、ペンチル、イソペンチル、tert−ペンチル、ヘキシル、イソヘキシル及び当該技術分野の通常の技術及び本明細書に示す教示に照らして上記の例のいずれか1つに相当すると見なされる基が挙げられる。幾つかの実施形態において、アルキルとは、直鎖又は分岐鎖炭化水素基を指す。これらの実施形態における具体的な実施例は、メチル、エチル、プロピル(例えば、n−プロピル及びイソプロピル)、ブチル(例えば、n−ブチル及びt−ブチル)、ヘキシル及びこれらに類するものである。
これらの塩、溶媒和物及び水和物を包含する本発明の化合物は、ヒトをはじめとする哺乳類の中枢神経系障害を治療する目的に使用できる。
本発明は、医薬品(例えばヒト用又は動物用医薬品)に使用するための、治療有効量の式Iの化合物、又はこれらの医薬的に許容される塩、溶媒和物、多形体、若しくはN−酸化物を含む医薬組成物を、更に提供するものである。幾つかの実施形態において、本組成物は、医薬的に許容される担体を更に含む。
■ 三環系抗鬱薬、例えば、イミプラミン、デシプラミン、クロミプラミン、アミトリプチリン、
■ 四環系抗鬱薬、例えば、ミアンセリン、
■ セロトニン/ノルアドレナリン再取り込み阻害剤(SNRI)、例えば、ベンラファキシン、
■ 選択的セロトニン再取り込み阻害薬(SSRI)、例えば、シタロプラム、フルオキセチン、パロキセチン、
■ 選択的ノルアドレナリン再取り込み阻害剤、例えば、レボキセチン、
■ モノアミンオキシダーゼ阻害剤、例えば、トラニルシプロミン、モクロベミド、及び
■ 他の抗鬱薬、例えば、オキシトリプタン、アゴメラチン、が挙げられる。
本明細書で使用される略語及び頭字語は以下の通りである。
中間体(1):SEM−ピラゾロ−4−ボロン酸ピナコールエステルの合成:
1.23g(32mmol)のLiAlH4をTHF(100mL)中に溶かした懸濁液に、5−プロピル−1H−ピラゾール−3−カルボン酸エチルエステル(1.82g、10mmol)のTHF(50mL)溶液を、0℃にて少量加えた。0℃にて1時間、及び室温にて12時間撹拌した後、混合物を水とメタノールの溶液(v/v、85:15)(100mL)で加水分解した。金属水酸化物を濾過し、エタノールで洗浄した。
(5−プロピル−1H−ピラゾール−3−イル)−メタノール(840mg、6mmol)をジクロロメタン(25mL)に溶かした混合物に、0℃にて無希釈のSOCl2(100mL)を部分的に加え、室温にて12時間撹拌した。過剰なSOCl2を減圧蒸留によって除去した。残渣をエタノール(150mL)中に溶解し、濾過して、ジエチルエーテルを加えることにより、白色板状晶を生じた。収率:1.11g(95%)MS(ESI m/z)159.0[M+H]+
■ 5−(クロロメチル)−3−メチル−1H−ピラゾール塩酸塩、VitasMLabから入手可能、注文ID:BBL019538
■ 5−(クロロメチル)−1,3−ジメチル−1H−ピラゾール、ABCRから入手可能、注文ID:AB224372
■ 3−(クロロメチル)−1−メチル−1H−ピラゾール、ABCRから入手可能、注文ID:AB200747
■ 4−(クロロメチル)−1−メチル−1H−ピラゾール塩酸塩、Aldrichから入手可能、注文ID:CBR01696−1G
■ 4−(2−クロロエチル)−1H−ピラゾール塩酸塩、ABCRから入手可能、注文ID:AB266246
■ 3−(クロロメチル)−1−エチル−1H−ピラゾール塩酸塩、Fluorochemから入手可能、注文ID:313369
■ 4−(クロロエチル)−3,5−ジメチル−1H−ピラゾール、ChemDivから入手可能、注文ID:BB01−4360
■ 3−(クロロメチル)−1H−ピラゾール塩酸塩、ChemDivから入手可能、注文ID:BB20−2557
■ 4−(クロロメチル)−1−エチル−1H−ピラゾール塩酸塩、ChemDivから入手可能、注文ID:BB57−1549
■ 5−(クロロメチル)−1−エチル−1H−ピラゾール塩酸塩、ChemDivから入手可能、注文ID:BB57−3435
■ 3−(クロロメチル)−1−シクロペンチル−1H−ピラゾール、Enamineから入手可能、注文ID:EN300−84084
■ 3−(クロロメチル)−1−イソプロピル−1H−ピラゾール、Enamineから入手可能、注文ID:EN300−74576
■ 3−(クロロメチル)−1−(ペンタン−3−イル)−1H−ピラゾール、Enamineから入手可能、注文ID:EN300−84091
■ 4−(2−クロロエチル)−1−エチル−1H−ピラゾール、Enamineから入手可能、注文ID:BBV−34543900
■ 5−(2−クロロエチル)−1−エチル−1H−ピラゾール、Enamineから入手可能、注文ID:BBV−38136817
■ 4−(2−クロロエチル)−1−メチル−1H−ピラゾール、Enamineから入手可能、注文ID:BBV−41178358
■ 5−(2−クロロエチル)−1−メチル−1H−ピラゾール、Enamineから入手可能、注文ID:BBV−38136179
■ 4−(4−クロロフェニル)−1H−ピラゾール、Peakdale,UKから入手可能、注文ID:1002465
■ 4−(3,5−ジフルオロフェニル)−1H−ピラゾール、Peakdale,UKから入手可能、注文ID:3002914
■ 4−(4−ブロモフェニル)−1H−ピラゾール、ABCRから入手可能、注文ID:AB235347
■ 4−(3−ブロモフェニル)−1H−ピラゾール、ABCRから入手可能、注文ID:AB233743
■ 4−フェニル−1H−ピラゾール、Enamineから入手可能、注文ID:EN300〜07023、が挙げられる。
4−{2−[4−(4−クロロ−3−ジフルオロメトキシ−フェニル)−ピラゾール−1−イル]−エチル}−3,5−ジメチル−1H−ピラゾール(1.00g、2.83mmol)とコハク酸(1.00g、2.83mmol)との混合物にエタノール(30mL)を加え、この混合物を78℃まで加熱し、溶液が清澄になるまで5分間撹拌した。溶媒を蒸発させ、結果として得られた固体を減圧下で50℃にて一晩乾燥させて、実施例1(1.00g、2.83mmol)を白色固体として得た。コハク酸塩(C4H6O4)(融点:79〜81℃)
5−ブロモ−2−クロロ−ベンズアルデヒド(4.4g、20mmol)をジクロロメタン(DCM)(50mL)中に溶かした溶液に、DAST(ジエチルアミノ硫黄トリフルオリド)(4.03g、25mmol)を加え、窒素雰囲気下、室温にて混合物を18時間撹拌した。反応混合物を氷水中に入れて急冷し、DCMで抽出した。有機層を乾燥させて、濃縮した。収率:3.1g(64%)
5−ブロモ−2−フルオロ−ベンズアルデヒド(4.06g、20mmol)をDCM(50mL)中に溶かした溶液に、DAST(ジエチルアミノ硫黄トリフルオリド)(4.03g、25mmol)を加え、窒素雰囲気下、室温にて混合物を18時間撹拌した。反応混合物を氷水中に入れて急冷し、DCMで抽出した。有機層を乾燥させて、濃縮した。収率:2.74g(61%)
1−(5−ブロモ−2−フルオロ−フェニル)−エタノン(4.34g、20mmol)をDCM(50mL)中に溶かした溶液に、DAST(ジエチルアミノ硫黄トリフルオリド)(4.03g、25mmol)を加え、窒素雰囲気下、室温にて混合物を18時間撹拌した。
7.59(d、1H、J=8.27);7.90(d、1H、J=8.27);8.06(s、1H);8.39(s、1H)
酢酸銅(II)(110mg、0.6mmol)、ピリジン(0.08mL、1mmol)、1−メチル−1H−ピラゾール−5−ボロン酸ピナコールエステル及び4−(3,4−ジクロロフェニル)−1H−ピラゾール(383mg、1.8mmol)をDMF中で化合させ、95℃にて20時間撹拌した。水及び酢酸エチルを用いて抽出を行い、DCM/MeOH(95:5)を用い、フラッシュクロマトグラフィで粗生成物を精製した。
ラットNR1/NR2B受容体への特異的結合の阻害
オスのウィスターラット(180〜200g)をCO2チャンバ内で2分間窒息させて殺した。小脳以外の脳全体を取り除き、氷上で解剖して、密閉式バイアルに入れて−70℃にて保管した。
カルシウム流入アッセイ(Calcium 5 Assay Kit,Molecular Devices)を用い、試験化合物がNR1/NR2Bのアンタゴニストとして作用する能力を評価した。
hNR1/NR2Bでトランスフェクトされた安定なHEK細胞系を使用した。このテトラサイクリン誘発性の細胞系は、GRIN1(GeneBank受託番号NM_007327.2)及びGRIN2B(GeneBank受託番号NM_000834.3)でトランスフェクトされる。10% FCS及び1%ペニシリン/ストレプトマイシン(PenStrep)を補給したDMEM/F12含有の細胞培養フラスコ中で、細胞を培養し、更なる抗生物質を選択した。
培地を除去し、100μMの7−CKA含有のMg2+フリーHBPSを溶かした充填緩衝液(Molecular Devices)200μLを、37℃にて1時間かけて細胞に装入した。
トランスフェクトされた安定なヒトERG受容体を含むHEK細胞系を、アッセイに使用した。細胞どうしを付着して生育させ、10% FBS、1%非不可欠アミノ酸、1%ペニシリン/ストレプトマイシン及び400μg/mLのG418(Calbiochem)を含むDULBECCOSのMEM培地内で維持した。
オスのウィスターラット(180〜200g)をCO2チャンバ内で2分間窒息させて殺した。小脳以外の脳全体を取り除き、氷上で解剖して、密閉式バイアルに入れて−70℃にて保管した。
マウスの強制水泳試験(鬱病の動物モデル)において、本発明の化合物は100mg/kg以下の投与用量にて有意な抗鬱効果を示す。
Claims (22)
- 式(I):
nは1又は2であり、
Hetは、
R1及びR2は、各々独立に、水素;F、Cl、及びBrから選択されるハロゲン;ヒドロキシ、ハロゲン、C1〜3(ハロ)アルコキシ、及びC3〜6(ハロ)シクロアルキルから選択される少なくとも1つの置換基で任意選択的に置換された、C1〜6アルキル;ヒドロキシ、ハロゲン、C1〜3(ハロ)アルキル及びC1〜3(ハロ)アルコキシから選択される少なくとも1つの置換基で任意選択的に置換された、C3〜6シクロアルキル;ヒドロキシ、ハロゲン、C1〜3(ハロ)アルコキシ及びC3〜6(ハロ)シクロアルキルから選択される少なくとも1つの置換基で任意選択的に置換された、C1〜6アルコキシ;ヒドロキシ、ハロゲン、C1〜3(ハロ)アルキル及びC1〜3(ハロ)アルコキシから選択される少なくとも1つの置換基で任意選択的に置換された、−O−C3〜6シクロアルキル;少なくとも1つのハロゲン原子で任意選択的に置換された、−S−C1〜3アルキル;少なくとも1つのハロゲン原子で任意選択的に置換された、−SO2−C1〜3アルキル;及び−SF5から選択され、あるいは
R1及びR2は一緒になって、ヒドロキシ、ハロゲン、C1〜3(ハロ)アルキル及びC1〜3(ハロ)アルコキシから選択される少なくとも1つの置換基で任意選択的に置換された、5〜7員の炭素環式化合物;並びにO、S又はNであり得る1〜3つのヘテロ原子を含有し、ヒドロキシ、ハロゲン、C1〜3(ハロ)アルキル及びC1〜3(ハロ)アルコキシから選択される少なくとも1つの置換基で任意選択的に置換された、5〜7員の複素環を形成し、
R3及びR4は、各々独立に、水素;ハロゲン;少なくとも1つのハロゲン原子で任意選択的に置換された、C1〜5(ハロ)アルキルから選択され、但し、R3及びR4の少なくとも1つが水素であることを条件とし、
R5及びR6は、各々独立に、水素;ハロゲン;アミノ;ハロゲン、ヒドロキシ、C1〜3(ハロ)アルコキシ及びC3〜6(ハロ)シクロアルキルから選択される少なくとも1つの置換基で任意選択的に置換された、C1〜5アルキル;ヒドロキシ、ハロゲン、C1〜3(ハロ)アルコキシ、及びC3〜6(ハロ)シクロアルキルから選択される少なくとも1つの置換基で任意選択的に置換された、C1〜5アルコキシ;並びにヒドロキシ、ハロゲン、C1〜3(ハロ)アルキル及びC1〜3(ハロ)アルコキシから選択される少なくとも1つの置換基で任意選択的に置換された、C3〜6シクロアルキルから選択され、かつ
R7は、水素;ハロゲン、ヒドロキシ、C1〜3(ハロ)アルコキシ及びC3〜6(ハロ)シクロアルキルから選択される少なくとも1つの置換基で任意選択的に置換された、C1〜5アルキル;又はヒドロキシ、ハロゲン、C1〜3(ハロ)アルキル及びC1〜3(ハロ)アルコキシから選択される少なくとも1つの置換基で任意選択的に置換された、C3〜6シクロアルキルである)
の化合物、又はこれらの医薬的に許容される塩、溶媒和物、多形体、若しくはN−酸化物。 - nが1である、請求項1に記載の化合物。
- R1及びR2の少なくとも1つが水素ではない、請求項1に記載の化合物。
- R1及びR2の少なくとも1つが水素ではない、請求項2に記載の化合物。
- R1及びR2の少なくとも1つが、F、Cl、Br、C1〜4(ハロ)アルキル、C3〜6(ハロ)シクロアルキル、C1〜3(ハロ)アルコキシ、C1〜3(ハロ)アルコキシ−C1〜3(ハロ)アルキル、C3〜6(ハロ)シクロアルキル−C1〜3(ハロ)アルキル、及びC3〜6(ハロ)シクロアルキル−C1〜3(ハロ)アルコキシから選択される、請求項1に記載の化合物。
- R3及びR4は、各々独立に、水素、F、Cl、Br、及びC1〜3(ハロ)アルキルから選択され、但し、R3及びR4の少なくとも1つが水素であることを条件とする、請求項1に記載の化合物。
- Hetは、
R5及びR6は、各々独立に、水素;F;Cl;アミノ;ハロゲン、ヒドロキシ及びC1〜3(ハロ)アルコキシから選択される少なくとも1つの置換基で任意選択的に置換された、C1〜3アルキル;C1〜3(ハロ)アルコキシ;C3〜6(ハロ)シクロアルキル;並びにC3〜6(ハロ)シクロアルキル−C1〜3(ハロ)アルキルから選択され、かつ
R7は、水素;ハロゲン、ヒドロキシ、C1〜3(ハロ)アルコキシ及びC3〜6(ハロ)シクロアルキルから選択される少なくとも1つの置換基で任意選択的に置換された、C1〜3アルキル;又はヒドロキシ、ハロゲン、C1〜3(ハロ)アルキル及びC1〜3(ハロ)アルコキシから選択される少なくとも1つの置換基で任意選択的に置換された、C3〜6シクロアルキルである、請求項1に記載の化合物。 - nは1であり、
R1及びR2は、各々独立に、F、Cl、C1〜2(ハロ)アルキル、及びC1〜2(ハロ)アルコキシから選択され、
Hetは、
R3及びR4は、各々独立に、水素、F、及びClから選択され、但し、R3及びR4の少なくとも1つが水素であることを条件とし、
R5及びR6は、各々独立に、水素、C1〜3(ハロ)アルキル、C3〜6(ハロ)シクロアルキル、C3〜6(ハロ)シクロアルキル、及びC3〜6(ハロ)シクロアルキル−C1〜3(ハロ)アルキルから選択され、かつ
R7は、水素;ハロゲン、ヒドロキシ、C1〜3(ハロ)アルコキシ及びC3〜6(ハロ)シクロアルキルから選択される少なくとも1つの置換基で任意選択的に置換された、C1〜3アルキル;ヒドロキシ、ハロゲン、C1〜3(ハロ)アルキル及びC1〜3(ハロ)アルコキシから選択される少なくとも1つの置換基で任意選択的に置換された、C3〜5シクロアルキルである、請求項1に記載の化合物。 - 4−[2−[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]エチル]−3,5−ジメチル−1H−ピラゾール、
3−[[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]−1−メチルピラゾール、
5−[[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−[(1−メチルピラゾール−4−イル)メチル]ピラゾール、
4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−[(2−メチルピラゾール−3−イル)メチル]ピラゾール、
4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−(1H−ピラゾール−4−イルメチル)ピラゾール、
3−[[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]−1−エチルピラゾール、
4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−[2−(1H−ピラゾール−4−イル)エチル]ピラゾール、
4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−[2−(1−エチルピラゾール−4−イル)エチル]ピラゾール、
3−[[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]−1−(1−エチルプロピル)−ピラゾール、
3−[[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]−1−シクロペンチル−ピラゾール、
4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−[(3−メチル−1H−ピラゾール−5−イル)メチル]ピラゾール、
3−[[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]−5−エチル−1H−ピラゾール、
3−[[4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]−5−プロピル−1H−ピラゾール、
4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−[(5−メチル−1H−ピラゾール−4−イル)メチル]ピラゾール、
4−[4−クロロ−3−(ジフルオロメトキシ)フェニル]−1−[(5−エチル−1H−ピラゾール−4−イル)メチル]ピラゾール、
4−[3−(ジフルオロメトキシ)−4−フルオロ−フェニル]−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
4−[3−(ジフルオロメトキシ)−4−フルオロ−フェニル]−1−[(1メチルピラゾール−4−イル)メチル]ピラゾール、
4−[3−クロロ−5−(ジフルオロメトキシ)フェニル]−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
1,3−ジメチル−5−[[4−[3−(トリフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]ピラゾール、
1−メチル−3−[[4−[3−(トリフルオロメトキシ)フェニル]ピラゾール−1−イル]メチル]ピラゾール、
3−[[4−[4−クロロ−3−(ジフルオロメチル)フェニル]ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
5−[[4−[4−クロロ−3−(ジフルオロメチル)フェニル]ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
4−[4−クロロ−3−(ジフルオロメチル)フェニル]−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
4−[2−[4−[4−クロロ−3−(ジフルオロメチル)フェニル]ピラゾール−1−イル]エチル]−3,5−ジメチル−1H−ピラゾール、
4−[3−クロロ−5−(ジフルオロメチル)フェニル]−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
5−[[4−[4−クロロ−3−(トリフルオロメチル)フェニル]ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
3−[[4−[4−クロロ−3−(トリフルオロメチル)フェニル]ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
3−[[4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
5−[[4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]−1−[(1−メチルピラゾール−4−イル)メチル]ピラゾール、
4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]−1−[(2−メチルピラゾール−3−イル)メチル]ピラゾール、
4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]−1−(1H−ピラゾール−3−イルメチル)ピラゾール、
4−[2−[4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]ピラゾール−1−イル]エチル]−3,5−ジメチル−1H−ピラゾール、
4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]−1−[2−(1H−ピラゾール−4−イル)エチル]ピラゾール、
3−[[4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]ピラゾール−1−イル]メチル]−1−エチル−ピラゾール、
4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]−1−[(3−メチル−1H−ピラゾール−5−イル)メチル]ピラゾール、
3−[[4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]ピラゾール−1−イル]メチル]−5−エチル−1H−ピラゾール、
3−[[4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]ピラゾール−1−イル]メチル]−5−プロピル−1H−ピラゾール、
4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]−1−[(5−メチル−1H−ピラゾール−4−イル)メチル]ピラゾール、
4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]−1−[(5−エチル−1H−ピラゾール−4−イル)メチル]ピラゾール、
4−[3−(1,1−ジフルオロエチル)−4−フルオロ−フェニル]−1−(1H−ピラゾール−3−イルメチル)ピラゾール、
4−[3−(1,1−ジフルオロエチル)−4−フルオロ−フェニル]−1−[(1−メチルピラゾール−4−イル)メチル]ピラゾール、
4−[3−(1,1−ジフルオロエチル)−4−フルオロ−フェニル]−1−[(5−エチル−1H−ピラゾール−4−イル)メチル]ピラゾール、
4−[3−(ジフルオロメチル)−5−フルオロ−フェニル]−1−[2−(1H−ピラゾール−3−イルメチル]ピラゾール、
1,3−ジメチル−5−[[4−[3−(トリフルオロメチル)フェニル]ピラゾール−1−イル]メチル]ピラゾール、
1−メチル−3−[[4−[3−(トリフルオロメチル)フェニル]ピラゾール−1−イル]メチル]ピラゾール、
1−メチル−3−[[4−[4−(トリフルオロメチル)フェニル]ピラゾール−1−イル]メチル]ピラゾール、
1,3−ジメチル−5−[[4−[4−(トリフルオロメチル)フェニル]ピラゾール−1−イル]メチル]ピラゾール、
5−[[4−(3−フルオロ−4−メチル−フェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
5−[[4−(3−フルオロ−4−メチル−フェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
5−[[4−(4−フルオロ−3−メチル−フェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
3−[[4−(4−フルオロ−3−メチル−フェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
4−(4−フルオロ−3−メチル−フェニル)−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
5−[[4−(4−クロロ−3−メチル−フェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
3−[[4−(4−クロロ−3−メチル−フェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
3−[[4−(4−クロロ−3−フルオロ−フェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
5−[[4−(4−クロロ−3−フルオロ−フェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
3−[[4−(3−クロロ−4−フルオロ−フェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
5−[[4−(3−クロロ−4−フルオロ−フェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
3−[[4−(3,4−ジクロロフェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
5−[[4−(3,4−ジクロロフェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
5−[[4−(2,4−ジクロロフェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
3−[[4−(2,4−ジクロロフェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
3−[[4−(4−フルオロ−2−メトキシ−フェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
5−[[4−(4−フルオロ−2−メトキシ−フェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
4−(3−シクロプロピルフェニル)−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
4−(3−メチルスルホニルフェニル)−1−(1H−ピラゾール−3−イルメチル)−ピラゾール、
1−メチル−4−[[4−(3−メチルスルホニルフェニル)ピラゾール−1−イル]メチル]−ピラゾール、
ペンタフルオロ−[3−[1−(1H−ピラゾール−3−イルメチル)ピラゾール−4−イル]]フェニル]−スルファン、
4−[2−[4−(4−クロロフェニル)−ピラゾール−1−イル]エチル]−3,5−ジメチル−1H−ピラゾール、
5−[[4−(4−クロロフェニル)−ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
3−[[4−(4−クロロフェニル)−ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
4−(4−クロロフェニル)−1−[(2−メチルピラゾール−3−イル)メチル]ピラゾール、
4−(4−クロロフェニル)−1−(1H−ピラゾール−3−イルメチル)ピラゾール、
4−(4−クロロフェニル)−1−[(1−メチルピラゾール−4−イル)メチル]ピラゾール、
3−[[4−(4−ブロモフェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
5−[[4−(4−ブロモフェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
5−[[4−(3−ブロモフェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
3−[[4−(3−ブロモフェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
5−[[4−(3,5−ジフルオロフェニル)ピラゾール−1−イル]メチル]−1,3−ジメチル−ピラゾール、
3−[[4−(3,5−ジフルオロフェニル)ピラゾール−1−イル]メチル]−1−メチル−ピラゾール、
1−メチル−3−[(4−フェニルピラゾール−1−イル)メチル]ピラゾール、
1,3−ジメチル−5−[(4−フェニルピラゾール−1−イル)メチル]ピラゾール、及び
1−メチル−5−[(4−フェニルピラゾール−1−イル)メチル]ピラゾール、並びに
これらの医薬的に許容される塩、溶媒和物、多形体、又はN−酸化物からなる群から選択される、請求項1に記載の化合物。 - 4−[[4−(3−ジフルオロメトキシ−4−クロロ−フェニル)ピラゾール−1−イル]メチル]−3,5−ジメチル−1H−ピラゾール、
4−[[4−(3−ジフルオロメチル−4−フルオロ−フェニル)ピラゾール−1−イル]メチル]−3,5−ジメチル−1H−ピラゾール、
4−[[4−(3−(1,1−ジフルオロエチル−4−フルオロ−フェニル)ピラゾール−1−イル]メチル]−3,5−ジメチル−1H−ピラゾール、
3−[[4−[3−(ジフルオロメトキシ)−4−フルオロ−フェニル]ピラゾール−1−イル]メチル]−4−エチル−1H−ピラゾール、
3−[[4−[3−(ジフルオロメチル)−4−フルオロ−フェニル]ピラゾール−1−イル]メチル]−4−エチル−1H−ピラゾール、
3−[[4−(3−(1,1−ジフルオロエチル)−フェニル)ピラゾール−1−イル]メチル]−1H−ピラゾール(マレイン酸塩として)、及び
3−[[4−(3−(ジフルオロメトキシ)−フェニル)ピラゾール−1−イル]メチル]−1H−ピラゾール(マレイン酸塩として)、並びに
これらの医薬的に許容される塩、溶媒和物、多形体、又はN−酸化物からなる群から選択される、請求項1に記載の化合物。 - 4−(4−クロロ−3−(ジフルオロメチル)フェニル)−1−((1−エチル−1H−イミダゾール−5−イル)メチル)−1H−ピラゾール、
4−(4−クロロフェニル)−1−((1−エチル−1H−イミダゾール−5−イル)メチル)−1H−ピラゾール、
4−(3,4−ジクロロフェニル)−2’−メチル−2’H−1,3’−ビピラゾール、
4−(3−クロロ−4−フルオロフェニル)−2’−メチル−2’H−1,3’−ビピラゾール、
2−((4−(4−クロロフェニル)−1H−ピラゾール−1−イル)メチル)イミダゾ[1,2−a]ピリジン、
3−(3−(ジフルオロメチル)−4−フルオロフェニル)−1−((5−((4−(3−(ジフルオロメチル)−4−フルオロフェニル)−1H−ピラゾール−1−イル)メチル)−1H−ピラゾール−3−イル)メチル)−1H−ピラゾール、及び
2−(1−((1−メチル−1H−ピラゾール−3−イル)メチル)−1H−ピラゾール−4−イル)ピリジン、並びに
これらの医薬的に許容される塩、溶媒和物、多形体、又はこれらのN−酸化物からなる群から選択される、請求項1に記載の化合物。 - 治療有効量の請求項1に記載の化合物、又はこれらの医薬的に許容される塩、溶媒和物、多形体、若しくはN−酸化物、及び少なくとも1つの医薬的に許容される賦形剤を含む、医薬組成物。
- 第2の活性成分を更に含む、請求項12に記載の医薬組成物。
- 治療有効量の請求項1に記載の化合物、又はこれらの医薬的に許容される塩、溶媒和物、多形体、若しくはN−酸化物を必要とする患者に投与することを含む、NMDA受容体の活動過多に関連する疾病、障害又は病気を治療する方法。
- GluN2B受容体により媒介される前記障害、疾病又は病気が、双極性障害、大鬱病性障害、治療抵抗性鬱病、産後鬱病、季節性感情障害、アルツハイマー病、パーキンソン病、ハンチントン舞踏病、多発性硬化症、認知障害、頭部損傷、脊髄損傷、卒中、てんかん、ジスキネジア、筋萎縮性側索硬化症、細菌性若しくは慢性感染症に関連する神経変性、疼痛、糖尿病性神経障害、片頭痛、脳虚血、精神分裂症、脳炎、自閉症及び自閉症スペクトラム障害、記憶及び学習障害、強迫性障害、注意力欠陥多動性障害(ADHD)、並びに中毒性疾患からなる群から選択される、請求項14に記載の方法。
- 治療有効量の請求項1に記載の化合物、又はこれらの医薬的に許容される塩、溶媒和物、多形体、若しくはN−酸化物を必要とする患者に投与することを含む、GluN2B受容体により媒介される疾病、障害又は病気の治療方法。
- GluN2B受容体により媒介される前記障害、疾病又は病気が、治療抵抗性の鬱病及び大鬱病性障害からなる群から選択される、請求項16に記載の方法。
- 患者に、治療有効量の請求項1に記載の化合物、又はこれらの医薬的に許容される塩、溶媒和物、多形体、若しくはN−酸化物を投与することを含む、それを必要とする患者における疾病、障害又は病気を治療する方法。
- 前記疾病又は障害が中枢神経系障害である、請求項18に記載の方法。
- 前記疾病又は障害が神経若しくは精神障害である、請求項18に記載の方法。
- 前記疾病又は障害が、(1)気分障害、(2)神経性、ストレス関連又は身体表現性障害、(3)心理的発育、(4)生理的撹乱及び身体的要因、(5)錐体路外障害及び運動障害に関連する行動症候群、(6)偶発性若しくは発作性、(7)疼痛、(8)神経変性形態、あるいは(9)脳血管疾患である、請求項18に記載の方法。
- 前記神経性、ストレス関連又は身体表現性障害が、不安障害であり、前記偶発性又は発作性障害がてんかんであり、かつ前記脳血管疾患が急性脳血管疾患又は慢性脳血管疾患である、請求項21に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462037815P | 2014-08-15 | 2014-08-15 | |
US62/037,815 | 2014-08-15 | ||
US201562146629P | 2015-04-13 | 2015-04-13 | |
US62/146,629 | 2015-04-13 | ||
PCT/US2015/045413 WO2016025918A1 (en) | 2014-08-15 | 2015-08-14 | Pyrazoles |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017525700A true JP2017525700A (ja) | 2017-09-07 |
JP2017525700A5 JP2017525700A5 (ja) | 2018-09-20 |
JP6618525B2 JP6618525B2 (ja) | 2019-12-11 |
Family
ID=54261065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017508553A Active JP6618525B2 (ja) | 2014-08-15 | 2015-08-14 | ピラゾール類 |
Country Status (9)
Country | Link |
---|---|
US (2) | USRE49517E1 (ja) |
EP (1) | EP3180315B1 (ja) |
JP (1) | JP6618525B2 (ja) |
DK (1) | DK3180315T3 (ja) |
ES (1) | ES2791252T3 (ja) |
HU (1) | HUE049278T2 (ja) |
PL (1) | PL3180315T3 (ja) |
PT (1) | PT3180315T (ja) |
WO (1) | WO2016025918A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3180329T3 (da) | 2014-08-15 | 2020-04-06 | Janssen Pharmaceuticals Inc | Triazoler som nr2b receptorinhibitorer |
KR20180026760A (ko) | 2015-07-09 | 2018-03-13 | 얀센 파마슈티카 엔.브이. | 치환된 4-아자인돌 및 glun2b 수용체 조절제로서의 이의 용도 |
SG11201806750WA (en) | 2016-02-10 | 2018-09-27 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators |
US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
US11447503B2 (en) | 2019-06-14 | 2022-09-20 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as GLUN2B receptor modulators |
MA52244A (fr) | 2018-04-04 | 2021-02-17 | Janssen Pharmaceutica Nv | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
PE20220386A1 (es) | 2019-06-14 | 2022-03-18 | Janssen Pharmaceutica Nv | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b |
EP3983073A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators |
CN114008052A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途 |
KR20220020915A (ko) | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | GluN2B 수용체 조절제로서의 피라진 카르바메이트 및 이들의 용도 |
EP3982958A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004523535A (ja) * | 2001-01-29 | 2004-08-05 | エフ.ホフマン−ラ ロシュ アーゲー | イミダゾール誘導体 |
WO2009028543A1 (ja) * | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 置換ピラゾール誘導体 |
JP2010527974A (ja) * | 2007-05-25 | 2010-08-19 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 代謝型グルタミン酸受容体2(mglu2受容体)の陽性調節剤としての複素環化合物 |
JP2011516417A (ja) * | 2008-03-27 | 2011-05-26 | エヴォテック・ノイロサイエンシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Nmdanr2b−サブタイプ選択的アンタゴニストを使用する障害の処置方法 |
WO2013130855A1 (en) * | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005534618A (ja) | 2002-03-28 | 2005-11-17 | エーザイ株式会社 | 神経変性疾患用の、c−junn−末端キナーゼ阻害剤としての7−アザインドール |
AU2005214375A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
WO2007065655A1 (en) | 2005-12-07 | 2007-06-14 | Neurosearch Sweden Ab | Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission |
US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
US20100249164A1 (en) | 2007-10-31 | 2010-09-30 | Renger John J | Modulation of sleep with nr2b receptor antagonists |
JP5411927B2 (ja) | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr1アンタゴニストとしてのピラゾール化合物 |
PT2308877E (pt) | 2008-08-05 | 2014-05-02 | Daiichi Sankyo Co Ltd | Derivados de imidazopiridin-2-ona |
BRPI0920354A2 (pt) | 2008-10-16 | 2017-06-27 | Addex Pharmaceuticals Sa | derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos |
JP5930278B2 (ja) | 2008-11-25 | 2016-06-08 | ユニバーシティー オブ ロチェスター | Mlk阻害剤および使用方法 |
NZ603446A (en) | 2010-04-14 | 2014-05-30 | Array Biopharma Inc | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases |
WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
JP2016516710A (ja) | 2013-03-13 | 2016-06-09 | アッヴィ・インコーポレイテッド | ピリジン系cdk9キナーゼ阻害薬 |
DK3180329T3 (da) | 2014-08-15 | 2020-04-06 | Janssen Pharmaceuticals Inc | Triazoler som nr2b receptorinhibitorer |
KR20180026760A (ko) | 2015-07-09 | 2018-03-13 | 얀센 파마슈티카 엔.브이. | 치환된 4-아자인돌 및 glun2b 수용체 조절제로서의 이의 용도 |
SG11201806750WA (en) | 2016-02-10 | 2018-09-27 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
-
2015
- 2015-08-14 JP JP2017508553A patent/JP6618525B2/ja active Active
- 2015-08-14 HU HUE15775837A patent/HUE049278T2/hu unknown
- 2015-08-14 ES ES15775837T patent/ES2791252T3/es active Active
- 2015-08-14 PT PT157758376T patent/PT3180315T/pt unknown
- 2015-08-14 WO PCT/US2015/045413 patent/WO2016025918A1/en active Application Filing
- 2015-08-14 US US17/124,879 patent/USRE49517E1/en active Active
- 2015-08-14 US US15/503,875 patent/US10155727B2/en not_active Ceased
- 2015-08-14 EP EP15775837.6A patent/EP3180315B1/en active Active
- 2015-08-14 DK DK15775837.6T patent/DK3180315T3/da active
- 2015-08-14 PL PL15775837T patent/PL3180315T3/pl unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004523535A (ja) * | 2001-01-29 | 2004-08-05 | エフ.ホフマン−ラ ロシュ アーゲー | イミダゾール誘導体 |
JP2010527974A (ja) * | 2007-05-25 | 2010-08-19 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 代謝型グルタミン酸受容体2(mglu2受容体)の陽性調節剤としての複素環化合物 |
WO2009028543A1 (ja) * | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 置換ピラゾール誘導体 |
JP2011516417A (ja) * | 2008-03-27 | 2011-05-26 | エヴォテック・ノイロサイエンシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Nmdanr2b−サブタイプ選択的アンタゴニストを使用する障害の処置方法 |
WO2013130855A1 (en) * | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
Non-Patent Citations (1)
Title |
---|
REGISTRY(STN)[ONLINE], JPN7019001277, ISSN: 0004024928 * |
Also Published As
Publication number | Publication date |
---|---|
JP6618525B2 (ja) | 2019-12-11 |
US20170275254A1 (en) | 2017-09-28 |
ES2791252T3 (es) | 2020-11-03 |
EP3180315A1 (en) | 2017-06-21 |
US10155727B2 (en) | 2018-12-18 |
EP3180315B1 (en) | 2020-03-18 |
DK3180315T3 (da) | 2020-04-06 |
USRE49517E1 (en) | 2023-05-02 |
PT3180315T (pt) | 2020-05-27 |
WO2016025918A1 (en) | 2016-02-18 |
HUE049278T2 (hu) | 2020-09-28 |
PL3180315T3 (pl) | 2020-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6618525B2 (ja) | ピラゾール類 | |
JP6605020B2 (ja) | Nr2b受容体阻害剤としてのトリアゾール | |
JP4740115B2 (ja) | 置換ピラゾール | |
TWI428334B (zh) | 作為5-ht6拮抗劑之磺醯基吡唑及磺醯基吡唑啉的甲脒衍生物 | |
CN110234638B (zh) | 杂芳基苯氧基苯甲酰胺kappa阿片类配体 | |
JP2005523310A (ja) | 置換インドール | |
JP2009528315A (ja) | シグマ受容体阻害剤としてのピラゾール誘導体 | |
NZ582520A (en) | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors | |
JP2021510151A (ja) | アルツハイマー病等のタウ凝集体に関連する障害の治療、緩和、または予防のための1,3,4,5−テトラヒドロ−2h−ピリド(4,3−b)インドール誘導体 | |
WO2011072207A1 (en) | Azocyclic inhibitors of fatty acid amide hydrolase | |
JP4740116B2 (ja) | 精神疾患および神経障害の処置のための5−ht受容体アンタゴニスト | |
JP2009528318A (ja) | シグマ受容体化合物 | |
JP2011153144A (ja) | 置換ピラゾール化合物 | |
JP2011513295A (ja) | インダゾール誘導体 | |
EP3055293A1 (en) | Diarylalkylamine rev-erb antagonists and their use as medicaments | |
JP4833832B2 (ja) | ピラゾール化合物 | |
MX2011001070A (es) | Nuevos derivados de difenil 1,2,3-triazol utiles como moduladores de los receptores de acetilcolina nicotinicos. | |
WO2016067143A1 (en) | N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels | |
JP6941235B2 (ja) | イミダゾピリジン誘導体及び薬物としてのその使用 | |
JP6656246B2 (ja) | プロキネチシン介在消化器疾患を治療するためのスルホニルピペリジン誘導体及びその使用 | |
JP2013231000A (ja) | 3−アミノメチルピラゾール誘導体 | |
KR20100072037A (ko) | 칸나비노이드 cb₁수용체 효능제로서의 5-아릴-4,5-디하이드로-(1h)-피라졸 | |
JP2010534231A (ja) | デュシェンヌ型筋ジストロフィーを治療するための化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180813 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180813 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190507 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190806 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191015 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191112 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6618525 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |